Feed:All articles: Difference between revisions

{"articlesQuery":{"topic":"all","articles":[{"timestamp":"2013-08-10T02:59:37Z","briefDesignDescription":"Simvastatin in stable CAD","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)90566-5/abstract","pageid":1587,"pdfurl":"","trainingLevel":"Student","citation":"Pedersen TR, <i>et al</i>. \"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)\". <i>The Lancet</i>. 1994. 344(8934):1383-1389.","subspecialties":"Cardiology","expansion":"Scandinavian Simvastatin Survival Study","briefResultsDescription":"Simvastatin reduces all mortality in stable CAD","published":"1994-11-19","pageName":"4S","diseases":"Hyperlipidemia;Coronary Artery Disease","abbreviation":"4S","title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","pmid":"7968073"},{"timestamp":"2014-06-13T04:27:16Z","briefDesignDescription":"ISDN/hydralazine for blacks with HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa042934","pageid":41,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa042934","trainingLevel":"Student\n}}","citation":"Taylor AL, <i>et al</i>. \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure\". <i>The New England Journal of Medicine</i>. 2004. 351(20):2049-2057.","subspecialties":"Cardiology","expansion":"African-American Heart Failure Trial","briefResultsDescription":"Improved survival among blacks with HF","published":"2004-11-11","pageName":"A-HeFT","diseases":"Heart Failure","abbreviation":"A-HeFT","title":"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure","pmid":"15533851"},{"timestamp":"2014-05-23T21:17:56Z","briefDesignDescription":"Benazepril/amlodipine vs. benazepril/HCTZ in HTN","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0806182","pageid":1448,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0806182","trainingLevel":"Resident\n}}","citation":"Jamerson K, <i>et al</i>. \"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2008. 359(23):2417-2428.","subspecialties":"Cardiology","expansion":"Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension","briefResultsDescription":"Benazepril/amlodipine is associated with fewer CV events","published":"2008-12-04","pageName":"ACCOMPLISH","diseases":"Hypertension","abbreviation":"ACCOMPLISH","title":"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients","pmid":"19052124"},{"timestamp":"2014-06-08T20:58:08Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802743","pageid":105,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802743","trainingLevel":"Intern","citation":"Gerstein HC, <i>et al</i>. \"Effects of Intensive Glucose Lowering in Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2008. 358(24):2545-59.","subspecialties":"Endocrinology","expansion":"Action to Control Cardiovascular Risk in Diabetes","briefResultsDescription":"Increased mortality and no cardiovascular benefit with intensive glycemic control","published":"2008-06-12","pageName":"ACCORD","diseases":"Diabetes Mellitus","abbreviation":"ACCORD","title":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","pmid":"18539917"},{"timestamp":"2014-11-17T10:58:53Z","briefDesignDescription":"Intensive BP control in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1001286","pageid":1760,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001286","trainingLevel":"Student\n}}","citation":"ACCORD Study Group. \"Effects of intensive blood-pressure control in type 2 diabetes mellitus\". <i>The New England Journal of Medicine</i>. 2010. 362(17):1575-1585.","subspecialties":"Endocrinology","expansion":"ACCORD Study Group","briefResultsDescription":"Intensive BP control doesn't reduce CV events in T2DM","published":"2010-03-14","pageName":"ACCORD BP","diseases":"Diabetes Mellitus","abbreviation":"ACCORD BP","title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","pmid":"20228401"},{"timestamp":"2014-10-23T16:16:16Z","briefDesignDescription":"ASA/clopidogrel vs. ASA in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0901301","pageid":360,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0901301","trainingLevel":"Resident\n}}","citation":"Connolly SJ, <i>et al</i>. \"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2009. 360(20):2066-78.","subspecialties":"Cardiology;Neurology","expansion":"Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events","briefResultsDescription":"ASA/clopidogrel  ↓ composite of stroke, non-CNS embolism, MI, or CV death and ↑ bleeding","published":"2009-05-14","pageName":"ACTIVE A","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ACTIVE A","title":"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation","pmid":"19336502"},{"timestamp":"2014-10-23T16:02:13Z","briefDesignDescription":"ASA/clopidogrel vs. warfarin in AF","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68845-4","pageid":1438,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606688454.pdf","trainingLevel":"Intern\n}}","citation":"Connolly SJ, <i>et al</i>. \"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.\". <i>The Lancet</i>. 2006. 367(9526):1903-12.","subspecialties":"Cardiology;Neurology","expansion":"Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events","briefResultsDescription":"Warfarin is superior to ASA/clopidogrel for stroke prevention in AF","published":"2006-06-10","pageName":"ACTIVE W","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ACTIVE W","title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.","pmid":"16765759"},{"timestamp":"2014-05-21T23:38:46Z","briefDesignDescription":"Cisatracurium in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1005372","pageid":1119,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005372","trainingLevel":"resident","citation":"Papazian L, <i>et al</i>. \"Neuromuscular blockers in early acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2010. 363(12):1107-1116.","subspecialties":"Critical Care","expansion":"ARDS et Curarisation Systematique","briefResultsDescription":"Cisatracurium improves 90-day survival and increases ventilator-free days","published":"2010-09-16","pageName":"ACURASYS","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"ACURASYS","title":"Neuromuscular blockers in early acute respiratory distress syndrome","pmid":"20843245"},{"timestamp":"2014-09-19T13:02:39Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802987","pageid":248,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802987","trainingLevel":"Intern","citation":"Patel A, <i>et al</i>. \"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2008. 358(24):2560-2572.","subspecialties":"Endocrinology","expansion":"Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation","briefResultsDescription":"Intensive therapy reduces microvascular complications","published":"2008-06-06","pageName":"ADVANCE","diseases":"Diabetes Mellitus","abbreviation":"ADVANCE","title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","pmid":"18539916"},{"timestamp":"2014-05-27T04:26:16Z","briefDesignDescription":"Rate vs. rhythm control in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa021328","pageid":87,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021328","trainingLevel":"Student\n}}","citation":"Wyse DG, <i>et al</i>. \"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2002. 347(23):1825-1833.","subspecialties":"Cardiology","expansion":"Atrial Fibrillation Follow-up Investigation of Rhythm Management","briefResultsDescription":"No mortality difference, trend towards harm with rhythm control","published":"2002-11-05","pageName":"AFFIRM","diseases":"Atrial Fibrillation","abbreviation":"AFFIRM","title":"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation","pmid":"12466506"},{"timestamp":"2014-11-05T19:18:59Z","briefDesignDescription":"Daily albumin in severe sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1305727","pageid":1781,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305727","trainingLevel":"resident\n}}","citation":"Caironi P, <i>et al</i>. \"Albumin replacement in patients with severe sepsis or septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1402-141.","subspecialties":"Critical Care","expansion":"Albumin Italian Outcome Sepsis","briefResultsDescription":"Daily albumin with no mortality benefit at 28 days","published":"2014-03-18","pageName":"ALBIOS","diseases":"Sepsis","abbreviation":"ALBIOS","title":"Albumin replacement in patients with severe sepsis or septic shock","pmid":"24635772"},{"timestamp":"2014-09-29T20:07:59Z","briefDesignDescription":"Chlorthalidone in HTN","fulltexturl":"http://jama.ama-assn.org/content/288/23/2981.long","pageid":171,"pdfurl":"http://jama.ama-assn.org/content/288/23/2981.full.pdf","trainingLevel":"Student","citation":"Wright JT, <i>et al</i>. \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic\". <i>Journal of the American Medical Association</i>. 2002. 288(23):2981-2997.","subspecialties":"Nephrology;Cardiology","expansion":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","briefResultsDescription":"Chlorthalidone performs similarly to lisinopril and amlodipine","published":"2002-12-18","pageName":"ALLHAT","diseases":"Hypertension","abbreviation":"ALLHAT","title":"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic","pmid":"12479763"},{"timestamp":"2014-10-23T17:16:49Z","briefDesignDescription":"Apixaban vs. warfarin in VTE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1302507","pageid":1609,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302507","trainingLevel":"Intern\n}}","citation":"Agnelli G, <i>et al</i>. \"Oral apixaban for the treatment of acute venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 369(9):799-808.","subspecialties":"Hematology;Pulmonology","expansion":"Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy","briefResultsDescription":"Apixaban noninferior to warfarin for VTE recurrence; less bleeding","published":"2013-07-01","pageName":"AMPLIFY","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis","abbreviation":"AMPLIFY","title":"Oral apixaban for the treatment of acute venous thromboembolism","pmid":"23808982"},{"timestamp":"2014-10-23T16:23:09Z","briefDesignDescription":"Apixaban after VTE treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1207541","pageid":1245,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1207541","trainingLevel":"Resident\n}}","citation":"Agnelli G, <i>et al</i>. \"Apixaban for extended treatment of venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 368(8):699-708.","subspecialties":"Hematology","expansion":"Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment","briefResultsDescription":"Apixaban reduces recurrent VTE","published":"2013-02-21","pageName":"AMPLIFY-EXT","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","abbreviation":"AMPLIFY-EXT","title":"Apixaban for extended treatment of venous thromboembolism","pmid":"23216615"},{"timestamp":"2013-06-05T02:56:47Z","briefDesignDescription":"Corticosteroids in septic shock","fulltexturl":"http://jama.jamanetwork.com/article.aspx?articleid","pageid":939,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4844/JCE10061.pdf","trainingLevel":"Resident","citation":"Annane D, <i>et al</i>. \"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock\". <i>Journal of the American Medical Association</i>. 2002. 288(7):862-871.","subspecialties":"Critical Care","expansion":"","briefResultsDescription":"Corticosteroids reduce mortality in septic shock with adrenal insufficiency","published":"2002-08-21","pageName":"Annane Trial","diseases":"Sepsis;Shock","abbreviation":"","title":"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock","pmid":"12186604"},{"timestamp":"2013-06-11T21:14:19Z","briefDesignDescription":"Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed","fulltexturl":"http://www.gastrojournal.org/article/S0016-5085(06)01535-6/fulltext","pageid":82,"pdfurl":"http://www.gastrojournal.org/article/S0016-5085(06)01535-6/pdf","trainingLevel":"Intern","citation":"Fernández J, <i>et al</i>. \"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage\". <i>Gastroenterology</i>. 2006. 131(4):1049-56.","subspecialties":"Gastroenterology;Infectious Disease","expansion":"","briefResultsDescription":"Ceftriaxone reduces the incidence of bacterial infection","published":"2006-10-01","pageName":"Antibiotics in Cirrhosis with Hemorrhage","diseases":"Cirrhosis;Gastrointestinal Hemorrhage","abbreviation":"","title":"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage","pmid":"17030175"},{"timestamp":"2013-06-19T04:39:10Z","briefDesignDescription":"Low vs. traditional volumes in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200005043421801","pageid":114,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200005043421801","trainingLevel":"Intern","citation":"Brower RG, <i>et al</i>. \"Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome\". <i>The New England Journal of Medicine</i>. 2000. 342(18):1301-1308.","subspecialties":"Critical Care","expansion":"Acute Respiratory Distress Syndrome Network","briefResultsDescription":"Mortality benefit and more ventilator-free days with lung-protective strategy","published":"2000-05-04","pageName":"ARDSNet","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"ARDSNet","title":"Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome","pmid":"10793162"},{"timestamp":"2014-11-02T20:42:32Z","briefDesignDescription":"EGDT vs. usual care in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1404380","pageid":2216,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1404380","trainingLevel":"Intern\n}}","citation":"ARISE and ANZICS writers. \"Goal-directed resuscitation for patients with early septic shock\". <i>The New England Journal of Medicine</i>. 2014. 371(16):1496-1506.","subspecialties":"Critical Care","expansion":"Australasian Resuscitation in Sepsis Evaluation","briefResultsDescription":"EGDT doesn't reduce mortality in sepsis","published":"2014-10-16","pageName":"ARISE","diseases":"Sepsis","abbreviation":"ARISE","title":"Goal-directed resuscitation for patients with early septic shock","pmid":"25272316"},{"timestamp":"2014-10-23T16:02:19Z","briefDesignDescription":"Apixaban vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1107039","pageid":1497,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1107039","trainingLevel":"Intern\n}}","citation":"Granger CB, <i>et al</i>. \"Apixaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 365(11):981-982.","subspecialties":"Cardiology;Neurology","expansion":"Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation","briefResultsDescription":"Apixaban better for CVA prevention in AF","published":"2011-09-15","pageName":"ARISTOTLE","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ARISTOTLE","title":"Apixaban versus warfarin in patients with atrial fibrillation","pmid":"21870978"},{"timestamp":"2014-10-17T10:52:43Z","briefDesignDescription":"Pirfenidone in IPF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1402582","pageid":1825,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402582","trainingLevel":"Fellow\n}}","citation":"King TE, <i>et al</i>. \"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis\". <i>The New England Journal of Medicine</i>. 2014. 370(22):2083-2092.","subspecialties":"Pulmonology","expansion":"Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis","briefResultsDescription":"Pirfenidone reduces progression of IPF","published":"2014-05-29","pageName":"ASCEND","diseases":"Pulmonary Fibrosis","abbreviation":"ASCEND","title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","pmid":"24836312"},{"timestamp":"2013-08-21T13:48:06Z","briefDesignDescription":"Aspirin after VTE treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1210384","pageid":1241,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210384","trainingLevel":"Intern","citation":"Brighton TA, <i>et al</i>. \"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2012. 367(21):1979-1987.","subspecialties":"Hematology","expansion":"Aspirin to Prevent Recurrent Venous Thromboembolism","briefResultsDescription":"ASA probably reduces recurrent VTE","published":"2012-11-04","pageName":"ASPIRE","diseases":"Venous Thromboembolism","abbreviation":"ASPIRE","title":"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism","pmid":"23121403"},{"timestamp":"2013-10-20T05:13:36Z","briefDesignDescription":"Revascularization in RAS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0905368","pageid":1684,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905368","trainingLevel":"Resident","citation":"Wheatley K, <i>et al</i>. \"Revascularization versus medical therapy for renal-artery stenosis\". <i>The New England Journal of Medicine</i>. 2009. 361(20):1953-1962.","subspecialties":"Nephrology","expansion":"Angioplasty and Stenting for Renal Artery Lesions","briefResultsDescription":"Revascularization no better than medical therapy alone in RAS","published":"2009-11-12","pageName":"ASTRAL","diseases":"Renal Artery Stenosis;Hypertension","abbreviation":"ASTRAL","title":"Revascularization versus medical therapy for renal-artery stenosis","pmid":"19907042"},{"timestamp":"2013-10-28T22:50:28Z","briefDesignDescription":"10y vs. 5y tamoxifen in breast cancer","fulltexturl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/","pageid":1581,"pdfurl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/fulltext","trainingLevel":"Fellow","citation":"Davies C, <i>et al</i>. \"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial\". <i>The Lancet</i>. 2013. 381(9869):805-16.","subspecialties":"Oncology","expansion":"Adjuvant Tamoxifen: Longer Against Shorter","briefResultsDescription":"10 years of tamoxifen reduces recurrence and mortality","published":"2013-03-09","pageName":"ATLAS","diseases":"Breast Cancer","abbreviation":"ATLAS","title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","pmid":"23219286"},{"timestamp":"2014-10-23T15:54:47Z","briefDesignDescription":"Rivaroxaban after ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1112277","pageid":174,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112277","trainingLevel":"Resident\n}}","citation":"Mega JL, <i>et al</i>. \"Rivaroxaban in Patients with Recent Acute Coronary Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 366(1):9-19.","subspecialties":"Cardiology","expansion":"Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51","briefResultsDescription":"Rivaroxaban reduces cardiovascular death, MI, and stroke, but increases nonfatal bleeding","published":"2012-01-05","pageName":"ATLAS ACS-2, TIMI 51","diseases":"Acute Coronary Syndrome;Coronary Artery Disease","abbreviation":"ATLAS ACS 2-TIMI 51","title":"Rivaroxaban in Patients with Recent Acute Coronary Syndrome","pmid":"22077192"},{"timestamp":"2014-10-23T16:02:26Z","briefDesignDescription":"Apixaban vs. ASA in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1007432","pageid":1718,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007432","trainingLevel":"Intern\n}}","citation":"Connolly SJ, <i>et al</i>. \"Apixaban in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 364(9):806-817.","subspecialties":"Cardiology;Neurology","expansion":"Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment","briefResultsDescription":"Apixaban better than ASA without increased bleeding in AF","published":"2011-03-03","pageName":"AVERROES","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"AVERROES","title":"Apixaban in patients with atrial fibrillation","pmid":"21309657"},{"timestamp":"2014-11-24T14:56:57Z","briefDesignDescription":"Zidovudine in HIV/AIDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198707233170401","pageid":1775,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198707233170401","trainingLevel":"Student\n}}","citation":"Fischl MA <i>et al</i>. \"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex\". <i>The New England Journal of Medicine</i>. 1987. 317(4):185-191.","subspecialties":"Infectious Disease","expansion":"","briefResultsDescription":"Zidovudine reduces mortality in HIV/AIDS","published":"1987-07-23","pageName":"AZT Trial","diseases":"HIV","abbreviation":"","title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex","pmid":"3299089"},{"timestamp":"2013-06-22T12:16:42Z","briefDesignDescription":"CABG/PCI vs. OMT in diabetes with CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805796","pageid":1471,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805796","trainingLevel":"Resident","citation":"Frye RL, <i>et al</i>. \"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2009. 360(24):2503-2515.","subspecialties":"Cardiology;Endocrinology","expansion":"Bypass Angioplasty Revascularization Investigation 2 Diabetes","briefResultsDescription":"CABG is superior to OMT in diabetics with CAD","published":"2009-06-11","pageName":"BARI 2D","diseases":"Coronary Artery Disease;Diabetes Mellitus","abbreviation":"BARI 2D","title":"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease","pmid":"19502645"},{"timestamp":"2014-12-01T14:21:22Z","briefDesignDescription":"DMARD ± prednisone or infliximab in RA","fulltexturl":"http://onlinelibrary.wiley.com/doi/10.1002/art.21405/abstract","pageid":77,"pdfurl":"http://onlinelibrary.wiley.com/doi/10.1002/art.21405/pdf","trainingLevel":"Resident","citation":"Goekoop-Ruiterman YP, <i>et al</i>. \"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis\". <i>Arthritis & Rheumatism</i>. 2005. 52(11):3381-3390.","subspecialties":"Rheumatology","expansion":"Behandel-Strategeieën (\"treatment strategies\" in Dutch)","briefResultsDescription":"Combination therapy produces early functional improvement than DMARD alone","published":"2005-11-01","pageName":"BeSt","diseases":"Rheumatoid Arthritis","abbreviation":"BeSt","title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis","pmid":"16258899"},{"timestamp":"2012-06-13T05:04:26Z","briefDesignDescription":"CT head rules for trauma","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04561-X/fulltext","pageid":93,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS014067360004561X.pdf","trainingLevel":"resident","citation":"Stiell IG, <i>et al</i>. \"The Canadian CT Head Rule for patients with minor head trauma\". <i>The Lancet</i>. 2001. 357(9266):1391-96.","subspecialties":"Emergency Medicine;Neurology","expansion":"","briefResultsDescription":"GCS score, skull fracture, emesis, age, amnesia, and mechanism predict risk","published":"2001-05-05","pageName":"Canadian CT Head Rule","diseases":"Trauma","abbreviation":"","title":"The Canadian CT Head Rule for patients with minor head trauma","pmid":"11356436"},{"timestamp":"2014-10-21T16:02:22Z","briefDesignDescription":"Clopidogrel vs. aspirin in CV disease","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)09457-3/fulltext","pageid":7,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673696094573.pdf","trainingLevel":"Intern","citation":"Gent M, <i>et al</i>. \"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events\". <i>The Lancet</i>. 1996. 348(9038):1329-39.","subspecialties":"Neurology;Cardiology","expansion":"Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events","briefResultsDescription":"Clopidogrel reduces risk of cardiovascular events","published":"1996-11-16","pageName":"CAPRIE","diseases":"Stroke;Transient Ischemic Attack;Coronary Artery Disease","abbreviation":"CAPRIE","title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events","pmid":"8918275"},{"timestamp":"2014-06-13T04:19:04Z","briefDesignDescription":"Ultrafiltration in decompensated HF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1210357","pageid":1356,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210357","trainingLevel":"Resident\n}}","citation":"Bart BA, <i>et al</i>. \"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 367(24):2296-2304.","subspecialties":"Cardiology","expansion":"Cardiorenal Rescue Study in Acute Decompensated Heart Failure","briefResultsDescription":"Ultrafiltration worse then meds in acute HF","published":"2012-12-13","pageName":"CARRESS-HF","diseases":"Heart Failure","abbreviation":"CARRESS-HF","title":"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome","pmid":"23131078"},{"timestamp":"2014-09-24T22:02:10Z","briefDesignDescription":"Antiarrhythmics post-MI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199103213241201","pageid":1110,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199103213241201","trainingLevel":"Resident","citation":"Echt DS, <i>et al</i>. \"Mortality and morbidity in patients receiving encainide, flecainide, or placebo\". <i>The New England Journal of Medicine</i>. 1991. 324(12):781-788.","subspecialties":"Cardiology","expansion":"Cardiac Arrhythmia Suppression Trial","briefResultsDescription":"Antiarrhythmics increase mortality","published":"1991-03-21","pageName":"CAST I","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"CAST I","title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","pmid":"1900101"},{"timestamp":"2012-06-19T22:07:32Z","briefDesignDescription":"Antipsychotics in schizophrenia","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa051688","pageid":419,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa051688","trainingLevel":"Resident","citation":"Lieberman JA, <i>et al</i>. \"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia\". <i>The New England Journal of Medicine</i>. 2005. 353(12):1209-23.","subspecialties":"Psychiatry","expansion":"Clinical Antipsychotic Trials of Intervention Effectiveness","briefResultsDescription":"Olanzapine ↓discontinuations but ↑metabolic syndrome, and perphenazine ˜ atypicals","published":"2005-09-22","pageName":"CATIE","diseases":"Schizophrenia","abbreviation":"CATIE","title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","pmid":"16172203"},{"timestamp":"2014-10-20T00:30:55Z","briefDesignDescription":"Ranibizumab vs. bevacizumab for macular degeneration","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1102673","pageid":2250,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102673","trainingLevel":"Resident","citation":"The CATT Research Group Writers. \"Ranibizumab and bevacizumab for neovascular age-related macular degeneration\". <i>The New England Journal of Medicine</i>. 2011. 364(20):1897-1908.","subspecialties":"Ophthalmology","expansion":"Comparison of Age-Related Macular Degeneration Treatment Trails","briefResultsDescription":"Ranibizumab vs. bevacizumab similar even when comparing monthly vs. PRN scheduling","published":"2011-05-19","pageName":"CATT","diseases":"Macular Degeneration","abbreviation":"CATT","title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","pmid":"21526923"},{"timestamp":"2013-08-05T13:18:59Z","briefDesignDescription":"ASA/clopidogrel vs. ASA in TIA/stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1215340","pageid":1530,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215340","trainingLevel":"Resident","citation":"Wang Y, <i>et al</i>. \"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack\". <i>The New England Journal of Medicine</i>. 2013. 369(1):11-19.","subspecialties":"Neurology","expansion":"Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events","briefResultsDescription":"ASA/clopidogrel decreases stroke rates compared to ASA alone in TIA and high-risk CVA","published":"2013-07-04","pageName":"CHANCE","diseases":"Stroke;Transient Ischemic Attack","abbreviation":"CHANCE","title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","pmid":"23803136"},{"timestamp":"2014-10-19T23:32:17Z","briefDesignDescription":"Aspirin/clopidogrel vs. aspirin for CV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa060989","pageid":2175,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa060989","trainingLevel":"Resident","citation":"Bhatt DL, <i>et al</i>. \"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events\". <i>The New England Journal of Medicine</i>. 2006. 354(16):1706-1717.","subspecialties":"Cardiology","expansion":"Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance","briefResultsDescription":"Combination therapy no better than aspirin alone, more bleeding","published":"2006-04-20","pageName":"CHARISMA","diseases":"Cardiovascular Disease;Stroke;Myocardial Infarction","abbreviation":"CHARISMA","title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","pmid":"16531616"},{"timestamp":"2014-08-29T20:13:54Z","briefDesignDescription":"ARB plus ACE-I in HF","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2914283-3/fulltext","pageid":2126,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603142833.pdf","trainingLevel":"Intern\n}}","citation":"McMurray JJ, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial\". <i>The Lancet</i>. 2003. 362(9386):767-771.","subspecialties":"Cardiology","expansion":null,"briefResultsDescription":"Adding ARB to ACE-I reduces CV events and HF hospitalizations","published":"2003-09-06","pageName":"CHARM-Added","diseases":"Heart Failure","abbreviation":"Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Added","title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial","pmid":"13678869"},{"timestamp":"2014-10-15T03:34:36Z","briefDesignDescription":"Nivolumab in solid tumors","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200690","pageid":2220,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200690","trainingLevel":"Resident\n}}","citation":"Topalian SL, <i>et al</i>. \"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer\". <i>The New England Journal of Medicine</i>. 2012. 366(26):2443-54.","subspecialties":"Oncology","expansion":"","briefResultsDescription":"Nivolumab was well tolerated, yielded durable remissions in about 30% of patients","published":"2012-06-28","pageName":"CheckMate-003","diseases":"Melanoma;Lung Cancer;Renal Cell Carcinoma","abbreviation":"","title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","pmid":"22658127"},{"timestamp":"2014-12-05T14:50:32Z","briefDesignDescription":"Free long-acting reversible contraception in teens","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1400506","pageid":2233,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400506","trainingLevel":"Student\n}}","citation":"Secura GM, <i>et al</i>. \"Provision of no-cost, long-acting contraception and teenage pregnancy\". <i>The New England Journal of Medicine</i>. 2014. 371(14):1316-1326.","subspecialties":"Gynecology;Preventive Medicine","expansion":null,"briefResultsDescription":"LARC reduced pregnancy, live births, and abortions","published":"2014-10-02","pageName":"CHOICE","diseases":"Unplanned Pregnancy","abbreviation":"CHOICE","title":"Provision of no-cost, long-acting contraception and teenage pregnancy","pmid":"25271604"},{"timestamp":"2012-05-07T01:52:13Z","briefDesignDescription":"EPO in CKD with anemia","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa065485","pageid":422,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa065485","trainingLevel":"Resident","citation":"Singh, AK <i>et al</i>. \"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease\". <i>The New England Journal of Medicine</i>. 2006. 355(20):2085-2098.","subspecialties":"Nephrology;Hematology","expansion":"Correction of Hemoglobin and Outcomes in Renal Insufficiency","briefResultsDescription":"Increased morbidity/mortality with higher hgb targets","published":"2006-11-16","pageName":"CHOIR","diseases":"Chronic Kidney Disease;Anemia","abbreviation":"CHOIR","title":"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease","pmid":"17108343"},{"timestamp":"2013-08-15T18:51:46Z","briefDesignDescription":"PFO closure in cryptogenic stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009639","pageid":1093,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009639","trainingLevel":"Fellow","citation":"Furlan AJ, <i>et al</i>. \"Closure or medical therapy for cryptogenic stroke with patent foramen ovale\". <i>The New England Journal of Medicine</i>. 2012. 366(11):991-999.","subspecialties":"Neurology;Cardiology","expansion":"Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent Foramen Ovale","briefResultsDescription":"PFO closure does not reduce recurrent stroke","published":"2012-03-15","pageName":"CLOSURE I","diseases":"Stroke;Patent Foramen Ovale;Transient Ischemic Attack","abbreviation":"CLOSURE I","title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","pmid":"22417252"},{"timestamp":"2014-10-23T17:17:06Z","briefDesignDescription":"LMWH vs. coumadin in cancer VTE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa025313","pageid":13,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa025313","trainingLevel":"Intern\n}}","citation":"Lee AY, <i>et al</i>. \"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer\". <i>The New England Journal of Medicine</i>. 2003. 349(2):146-53.","subspecialties":"Hematology;Oncology","expansion":"Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients With Venous Thromboembolism","briefResultsDescription":"LMWH reduces VTE recurrence in cancer VTE without increasing bleeding risk","published":"2003-07-10","pageName":"CLOT","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","abbreviation":"CLOT","title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","pmid":"12853587"},{"timestamp":"2012-06-20T01:47:52Z","briefDesignDescription":"PPI plus clopidogrel in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1007964","pageid":313,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007964","trainingLevel":"Resident","citation":"Bhatt DL, <i>et al</i>. \"Clopidogrel with or without omeprazole in coronary artery disease\". <i>The New England Journal of Medicine</i>. 2010. 363(20):1909-17.","subspecialties":"Cardiology","expansion":"Clopidogrel and the Optimization of Gastrointestinal Events Trial","briefResultsDescription":"PPIs reduce bleeding but do not increase CV events when given with clopidogrel","published":"2010-11-11","pageName":"COGENT","diseases":"Coronary Artery Disease","abbreviation":"COGENT","title":"Clopidogrel with or without omeprazole in coronary artery disease","pmid":"20925534"},{"timestamp":"2014-06-13T04:29:19Z","briefDesignDescription":"Carvedilol vs. metoprolol in HFrEF","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13800-7/fulltext","pageid":121,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603138007.pdf","trainingLevel":"Resident\n}}","citation":"Poole-Wilson PA, <i>et al</i>. \"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial\". <i>The Lancet</i>. 2003. 362(9377):7-13.","subspecialties":"Cardiology","expansion":"Carvedilol Or Metoprolol European Trial","briefResultsDescription":"Carvedilol extends survival in HFrEF","published":"2003-07-05","pageName":"COMET","diseases":"Heart Failure","abbreviation":"COMET","title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial","pmid":"12853193"},{"timestamp":"2014-09-24T20:08:16Z","briefDesignDescription":"Metoprolol in acute MI","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67661-1/fulltext","pageid":1451,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673605676611.pdf","trainingLevel":"Student\n}}","citation":"Chen ZM, <i>et al</i>. \"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial\". <i>The Lancet</i>. 2005. 366(9497):1622-1632.","subspecialties":"Cardiology","expansion":"ClOpidogrel and Metoprolol in Myocardial Infarction Trial / Second Chinese Cardiac Study","briefResultsDescription":"High-dose IV and PO metoprolol increases cardiogenic shock","published":"2005-11-05","pageName":"COMMIT","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"COMMIT/CCS-2","title":"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial","pmid":"16271643"},{"timestamp":"2014-06-13T04:30:42Z","briefDesignDescription":"Enalapril in severe HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198706043162301","pageid":18,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198706043162301","trainingLevel":"Intern\n}}","citation":"CONSENSUS Trial Study Group. \"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study\". <i>The New England Journal of Medicine</i>. 1987. 316(23):1429-35.","subspecialties":"Cardiology","expansion":"Cooperative North Scandinavian Enalapril Survival Study","briefResultsDescription":"Enalapril ↓mortality in NYHA class IV HFrEF","published":"1987-06-04","pageName":"CONSENSUS","diseases":"Heart Failure","abbreviation":"CONSENSUS","title":"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study","pmid":"2883575"},{"timestamp":"2014-06-13T04:33:43Z","briefDesignDescription":"Carvedilol in HFrEF","fulltexturl":"http://circ.ahajournals.org/content/106/17/2194.full","pageid":42,"pdfurl":"http://circ.ahajournals.org/content/106/17/2194.full.pdf","trainingLevel":"Intern\n}}","citation":"Packer M, <i>et al</i>. \"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure\". <i>Circulation</i>. 2002. 106(17):2194-9.","subspecialties":"Cardiology","expansion":"Carvedilol Prospective Randomized Cumulative Survival","briefResultsDescription":"Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HFrEF","published":"2002-10-22","pageName":"COPERNICUS","diseases":"Heart Failure","abbreviation":"COPERNICUS","title":"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure","pmid":"12390947"},{"timestamp":"2014-06-13T04:37:32Z","briefDesignDescription":"Rosuvastatin in ischemic HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0706201","pageid":524,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706201","trainingLevel":"Resident\n}}","citation":"Kjekshus J, <i>et al</i>. \"Rosuvastatin in Older Patients with Systolic Heart Failure\". <i>The New England Journal of Medicine</i>. 2007. 357(22):2248-61.","subspecialties":"Cardiology","expansion":"Controlled Rosuvastatin Multinational Trial in Heart Failure","briefResultsDescription":"Statins confer no survival benefit but may reduce hospitalizations in ischemic HFrEF","published":"2007-11-29","pageName":"CORONA","diseases":"Heart Failure;Hyperlipidemia","abbreviation":"CORONA","title":"Rosuvastatin in Older Patients with Systolic Heart Failure","pmid":"17984166"},{"timestamp":"2014-06-19T06:03:49Z","briefDesignDescription":"Hydrocortisone in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa071366","pageid":4,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa071366","trainingLevel":"Student","citation":"Sprung CL, <i>et al</i>. \"Hydrocortisone therapy for patients with septic shock\". <i>New England Journal of Medicine</i>. 2008. 358(2):111-24.","subspecialties":"Critical Care;Endocrinology","expansion":"Corticosteroid Therapy of Septic Shock","briefResultsDescription":"Improved survival of hydrocortisone in septic shock","published":"2008-01-10","pageName":"CORTICUS","diseases":"Sepsis;Shock","abbreviation":"CORTICUS","title":"Hydrocortisone therapy for patients with septic shock","pmid":"18184957"},{"timestamp":"2013-06-21T13:11:38Z","briefDesignDescription":"PCI vs. medical therapy in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa070829","pageid":21,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa070829","trainingLevel":"Student","citation":"Boden WE, <i>et al</i>. \"Optimal medical therapy with or without PCI for stable coronary disease\". <i>The New England Journal of Medicine</i>. 2007. 356:1503-16.","subspecialties":"Cardiology","expansion":"Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation","briefResultsDescription":"No difference between PCI and OMT in stable CAD","published":"2007-04-12","pageName":"COURAGE","diseases":"Coronary Artery Disease","abbreviation":"COURAGE","title":"Optimal medical therapy with or without PCI for stable coronary disease","pmid":"17387127"},{"timestamp":"2013-08-31T18:14:13Z","briefDesignDescription":"Tranexamic acid in trauma","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960835-5/fulltext","pageid":490,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673610608355.pdf","trainingLevel":"resident","citation":"Shakur H, <i>et al</i>. \"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage\". <i>The Lancet</i>. 2010. 376(9734):23-32.","subspecialties":"Emergency Medicine;Surgery","expansion":"Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2","briefResultsDescription":"Tranexamic acid reduces 4-week mortality","published":"2010-07-03","pageName":"CRASH-2","diseases":"Trauma","abbreviation":"CRASH-2","title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage","pmid":"20554319"},{"timestamp":"2013-08-15T18:50:20Z","briefDesignDescription":"Stenting vs. CEA in carotid stenosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0912321","pageid":492,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0912321","trainingLevel":"Intern","citation":"Brott TG, <i>et al</i>. \"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis\". <i>The New England Journal of Medicine</i>. 2010. 363(1):11-23.","subspecialties":"Surgery;Neurology;Cardiology","expansion":"Carotid Revascularization Endarterectomy vs. Stenting Trial","briefResultsDescription":"No difference in stroke/MI/death; stenting ↑perioperative stroke but ↓perioperative MI","published":"2010-07-01","pageName":"CREST","diseases":"Carotid Stenosis;Stroke;Transient Ischemic Attack","abbreviation":"CREST","title":"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis","pmid":"20505173"},{"timestamp":"2014-09-22T12:23:27Z","briefDesignDescription":"Colloids vs. crystalloids in shock","fulltexturl":"http://bit.ly/1kLbQWJ","pageid":1768,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/928522/joi130081.pdf","trainingLevel":"resident","citation":"Annane D, <i>et al</i>. \"Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock\". <i>The Journal of the American Medical Association</i>. 2013. 310(17):1809-1817.","subspecialties":"Critical Care","expansion":"Colloids Versus Crystalloids for the Resuscitation of the Critically Ill","briefResultsDescription":"Colloids no different from crystalloids in mortality","published":"2013-11-06","pageName":"CRISTAL","diseases":"Shock","abbreviation":"CRISTAL","title":"Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock","pmid":"24108515"},{"timestamp":"2013-08-07T13:19:01Z","briefDesignDescription":"Captopril in T1DM nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199311113292004","pageid":1591,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199311113292004","trainingLevel":"Student","citation":"Lewis EJ, <i>et al</i>. \"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.\". <i>The New England Journal of Medicine</i>. 1993. 329(20):1456-1462.","subspecialties":"Nephrology;Endocrinology","expansion":"Collaborative Study Group Captopril Trial","briefResultsDescription":"Captopril reduces T1DM nephropathy progression","published":"1993-11-11","pageName":"CSG Captopril Trial","diseases":"Diabetic Nephropathy;Diabetes Mellitus","abbreviation":"CSG Captopril Trial","title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.","pmid":"8413456"},{"timestamp":"2014-09-24T20:43:54Z","briefDesignDescription":"Clopidogrel in UA/NSTEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010746","pageid":921,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010746","trainingLevel":"Resident\n}}","citation":"Yusuf S, <i>et al</i>. \"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation\". <i>The New England Journal of Medicine</i>. 2001. 345(7):494-502.","subspecialties":"Cardiology","expansion":"Clopidogrel in Unstable Angina to Prevent Recurrent Events","briefResultsDescription":"Clopidogrel reduces CV events but increases bleeding in UA/NSTEMI","published":"2001-08-16","pageName":"CURE","diseases":"Acute Coronary Syndrome","abbreviation":"CURE","title":"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","pmid":"11519503"},{"timestamp":"2013-09-30T22:37:35Z","briefDesignDescription":"Scheduled daily sedation holidays in intubated patients","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200005183422002","pageid":1554,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200005183422002","trainingLevel":"Intern","citation":"Kress JP, <i>et al</i>. \"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation\". <i>The New England Journal of Medicine</i>. 2000. 342(20):1471-1477.","subspecialties":"Critical Care;Pulmonology","expansion":"","briefResultsDescription":"Sedation holidays reduce intubated, ICU, hospital days","published":"2000-05-18","pageName":"Daily ICU Sedation Holidays","diseases":"Respiratory Failure","abbreviation":"","title":"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation","pmid":"10816184"},{"timestamp":"2014-11-24T03:59:43Z","briefDesignDescription":"Aspirin/clopidogrel duration after PCI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1409312","pageid":2264,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409312","trainingLevel":"Intern\n}}","citation":"Mauri L, <i>et al</i>. \"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents\". <i>The New England Journal of Medicine</i>. 2014. ePub(2014-11-16):1-12.","subspecialties":"Cardiology","expansion":"Dual Antiplatelet Therapy","briefResultsDescription":"Longer dual antiplatelet therapy reduces stent thrombosis, MI, stroke, increases mortality and bleeding","published":"2014-11-16","pageName":"DAPT","diseases":"Coronary Artery Disease;Myocardial Infarction;Stroke","abbreviation":"DAPT","title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","pmid":"25399658"},{"timestamp":"2013-04-04T11:30:00Z","briefDesignDescription":"DASH diet in HTN","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199704173361601","pageid":90,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199704173361601","trainingLevel":"Student","citation":"Appel LJ, <i>et al</i>. \"A clinical trial of the effects of dietary patterns on blood pressure\". <i>The New England Journal of Medicine</i>. 1997. 336(16):1117-1124.","subspecialties":"Cardiology;Nephrology","expansion":"Dietary Approaches to Stop Hypertension","briefResultsDescription":"DASH diet reduces SBP and DBP","published":"1997-04-17","pageName":"DASH","diseases":"Hypertension","abbreviation":"DASH","title":"A clinical trial of the effects of dietary patterns on blood pressure","pmid":"9099655"},{"timestamp":"2012-09-16T11:23:12Z","briefDesignDescription":"Intensive glycemic therapy in T1DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199309303291401","pageid":135,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199309303291401","trainingLevel":"Student","citation":"DCCT Research Group. \"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus\". <i>The New England Journal of Medicine</i>. 1993. 329(14):977-986.","subspecialties":"Endocrinology","expansion":"Diabetes Control and Complications Trial","briefResultsDescription":"Intensive therapy delays microvascular but not macrovascular complications in T1DM","published":"1993-09-30","pageName":"DCCT","diseases":"Diabetes Mellitus","abbreviation":"DCCT","title":"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus","pmid":"8366922"},{"timestamp":"2014-06-13T04:45:33Z","briefDesignDescription":"ICD vs. medical therapy in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa033088","pageid":84,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa033088","trainingLevel":"Resident\n}}","citation":"Kadish A, <i>et al</i>. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2004. 350(21):2151-2158.","subspecialties":"Cardiology","expansion":"Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation","briefResultsDescription":"ICD reduced risk of arrhythmogenic sudden death, but not overall mortality","published":"2004-05-20","pageName":"DEFINITE","diseases":"Heart Failure","abbreviation":"DEFINITE","title":"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy","pmid":"15152060"},{"timestamp":"2014-06-13T04:50:56Z","briefDesignDescription":"Digoxin in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199702203360801","pageid":89,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199702203360801","trainingLevel":"Resident\n}}","citation":"Gorlin R, <i>et al</i>. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". <i>The New England Journal of Medicine</i>. 1997. 336(8):525-533.","subspecialties":"Cardiology","expansion":"Digitalis Investigation Group","briefResultsDescription":"Reduced hospitalizations, no mortality benefit","published":"1997-02-20","pageName":"DIG","diseases":"Heart Failure","abbreviation":"DIG","title":"The effect of digoxin on mortality and morbidity in patients with heart failure","pmid":"9036306"},{"timestamp":"2014-06-13T05:00:40Z","briefDesignDescription":"Diuretic dosing in acute HF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1005419","pageid":1457,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419","trainingLevel":"Intern\n}}","citation":"Felker GM, <i>et al</i>. \"Diuretic strategies in patients with acute decompensated heart failure\". <i>The New England Journal of Medicine</i>. 2011. 364(9):797-805.","subspecialties":"Cardiology","expansion":"Diuretic Optimization Strategies Evaluation","briefResultsDescription":"High-dose better than low-dose, continuous infusions no better than intermittent IV boluses","published":"2011-03-03","pageName":"DOSE","diseases":"Heart Failure","abbreviation":"DOSE","title":"Diuretic strategies in patients with acute decompensated heart failure","pmid":"21366472"},{"timestamp":"2013-07-29T21:18:41Z","briefDesignDescription":"Duct tape vs. cryotherapy for warts","fulltexturl":"","pageid":1579,"pdfurl":"http://archpedi.jamanetwork.com/data/Journals/PEDS/5052/POA20075.pdf","trainingLevel":"Student","citation":"Focht DR, <i>et al</i>. \"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)\". <i>Archives of Pediatric and Adolescent Medicine</i>. 2002. 156:971-974.","subspecialties":"Pediatrics;Dermatology","expansion":"","briefResultsDescription":"Duct tape superior to cryotherapy for wart resolution","published":"2002-10-01","pageName":"Duct Tape for Treatment of the Common Wart","diseases":"Warts","abbreviation":"","title":"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)","pmid":"12361440"},{"timestamp":"2013-08-16T00:33:17Z","briefDesignDescription":"Palliative care in NSCLC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1000678","pageid":466,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000678","trainingLevel":"Intern","citation":"Temel, JS <i>et al</i>. \"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2010. 363(8):733-742.","subspecialties":"Oncology;Palliative Care","expansion":null,"briefResultsDescription":"Palliative care ↑mood, ↑QOL, ↑survival, ↓aggressive care","published":"2010-08-19","pageName":"Early Palliative Care","diseases":"Lung Cancer","abbreviation":null,"title":"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer","pmid":"20818875"},{"timestamp":"2013-06-17T12:56:29Z","briefDesignDescription":"Alteplase 3-4.5h after stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0804656","pageid":115,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804656","trainingLevel":"Intern","citation":"Hacke W, <i>et al</i>. \"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 2008. 359(13):1317-1329.","subspecialties":"Neurology","expansion":"European Cooperative Acute Stroke Study III","briefResultsDescription":"Alteplase improves neurological outcomes at 3 months","published":"2008-09-25","pageName":"ECASS III","diseases":"Stroke","abbreviation":"ECASS III","title":"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke","pmid":"18815396"},{"timestamp":"2013-03-12T08:18:42Z","briefDesignDescription":"Intensive glycemic therapy in T1DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052187","pageid":136,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052187","trainingLevel":"intern","citation":"Nathan DM, <i>et al</i>. \"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes\". <i>The New England Journal of Medicine</i>. 2005. 353(25):2643-2653.","subspecialties":"Endocrinology","expansion":"Epidemiology of Diabetes Interventions and Complications","briefResultsDescription":"Intensive therapy associated with fewer cardiovascular complications","published":"2005-12-22","pageName":"EDIC","diseases":"Diabetes Mellitus","abbreviation":"EDIC","title":"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes","pmid":"16371630"},{"timestamp":"2014-10-23T16:22:58Z","briefDesignDescription":"Rivaroxaban vs. warfarin in PE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1113572","pageid":1519,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113572","trainingLevel":"Student\n}}","citation":"Büller HR, <i>et al</i>. \"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism\". <i>The New England Journal of Medicine</i>. 2012. 366(14):1287-1297.","subspecialties":"Hematology;Pulmonology","expansion":"","briefResultsDescription":"Rivaroxaban is noninferior to warfarin in PE treatment","published":"2012-04-05","pageName":"EINSTEIN-PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"EINSTEIN-PE","title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","pmid":"22449293"},{"timestamp":"2013-06-27T17:49:25Z","briefDesignDescription":"T-DM1 in metastatic breast cancer","fulltexturl":"http://www.nejm.org/doi/abs/10.1056/NEJMoa1209124","pageid":1257,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209124","trainingLevel":"fellow","citation":"Verma S, <i>et al</i>. \"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer\". <i>The New England Journal of Medicine</i>. 2012. 367(19):1783-1791.","subspecialties":"Oncology","expansion":"Emtansine vs. Capecitabine+Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer","briefResultsDescription":"T-DM1 prolongs PFS in metastatic breast cancer","published":"2012-11-08","pageName":"EMILIA","diseases":"Breast Cancer","abbreviation":"EMILIA","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","pmid":"23020162"},{"timestamp":"2014-06-13T05:16:42Z","briefDesignDescription":"Eplerenone in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009492","pageid":120,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492","trainingLevel":"Resident\n}}","citation":"Zannad F, <i>et al</i>. \"Eplerenone in patients with systolic heart failure and mild symptoms\". <i>The New England Journal of Medicine</i>. 2011. 364(1):11-21.","subspecialties":"Cardiology","expansion":"Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure","briefResultsDescription":"Eplerenone reduces CV deaths and HF hospitalizations","published":"2011-01-06","pageName":"EMPHASIS-HF","diseases":"Heart Failure","abbreviation":"EMPHASIS-HF","title":"Eplerenone in patients with systolic heart failure and mild symptoms","pmid":"21073363"},{"timestamp":"2014-06-13T05:20:42Z","briefDesignDescription":"Eplerenone post-MI with HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030207","pageid":16,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030207","trainingLevel":"Resident\n}}","citation":"Pitt B, <i>et al</i>. \"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2003. 348(14):1309-21.","subspecialties":"Cardiology","expansion":"Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","briefResultsDescription":"Mortality benefit of eplerenone post MI with HFrEF","published":"2003-04-03","pageName":"EPHESUS","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"EPHESUS","title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","pmid":"12668699"},{"timestamp":"2014-06-13T05:31:57Z","briefDesignDescription":"PA catheters in acute HF management","fulltexturl":null,"pageid":1407,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf","trainingLevel":"Resident\n}}","citation":"Binanay C, <i>et al</i>. \"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness\". <i>JAMA</i>. 2005. 294(13):1625-1633.","subspecialties":"Cardiology;Critical Care","expansion":"Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness","briefResultsDescription":"Routine PA catheters no better than clinical assessment","published":"2005-10-05","pageName":"ESCAPE","diseases":"Heart Failure","abbreviation":"ESCAPE","title":"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness","pmid":"16204662"},{"timestamp":"2014-05-11T10:19:18Z","briefDesignDescription":"ASA+dipyridamole in secondary stroke prevention","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968734-5/fulltext","pageid":1726,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606687345.pdf","trainingLevel":"Intern","citation":"Halkes PH, <i>et al</i>. \"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial\". <i>The Lancet</i>. 2006. 367(9523):1665-1673.","subspecialties":"Neurology","expansion":"European/Australasian Stroke Prevention in Reversible Ischaemia Trial","briefResultsDescription":"ASA+dipyridamole better than ASA for secondary stroke prevention","published":"2006-05-20","pageName":"ESPRIT","diseases":"Stroke;Transient Ischemic Attack","abbreviation":"ESPRIT","title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial","pmid":"16714187"},{"timestamp":"2014-09-26T17:56:38Z","briefDesignDescription":"LMWH vs. UFH in UA/NSTEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199708143370702","pageid":1443,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199708143370702","trainingLevel":"Intern\n}}","citation":"Cohen M, <i>et al</i>. \"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 1997. 337(7):447-452.","subspecialties":"Cardiology","expansion":"Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group","briefResultsDescription":"LMWH reduces 14-day mortality, MI, or recurrent angina in UA/NSTEMI","published":"1997-08-14","pageName":"ESSENCE","diseases":"Acute Coronary Syndrome","abbreviation":"ESSENCE","title":"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease","pmid":"9250846"},{"timestamp":"2013-03-12T08:23:06Z","briefDesignDescription":"Dexamethasone in meningitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa021334","pageid":306,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021334","trainingLevel":"Resident","citation":"de Gans JD, <i>et al</i>. \"Dexamethasone in Adults with Bacterial Meningitis\". <i>The New England Journal of Medicine</i>. 2002. 347(20):1549-1556.","subspecialties":"Infectious Disease;Neurology","expansion":"European Dexamethasone Study","briefResultsDescription":"Dexamethasone reduces mortality in bacterial meningitis","published":"2002-11-14","pageName":"European Dexamethasone Study","diseases":"Meningitis","abbreviation":"EDS","title":"Dexamethasone in Adults with Bacterial Meningitis","pmid":"12432041"},{"timestamp":"2014-06-13T05:39:33Z","briefDesignDescription":"Tolvaptan in acute HF if HFrEF","fulltexturl":null,"pageid":1345,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf","trainingLevel":"Resident\n}}","citation":"Konstam MA, <i>et al</i>. \"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure\". <i>The Journal of the American Medical Association</i>. 2007. 297(12):1319-1331.","subspecialties":"Cardiology","expansion":"Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan","briefResultsDescription":"No benefit from tolvaptan when given for 60 days after acute HF episode","published":"2007-03-28","pageName":"EVEREST-Outcomes","diseases":"Heart Failure","abbreviation":"EVEREST","title":"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure","pmid":"17384437"},{"timestamp":"2013-10-13T17:30:50Z","briefDesignDescription":"Omalizumab in severe allergic asthma","fulltexturl":null,"pageid":1434,"pdfurl":"http://annals.org/data/Journals/AIM/20231/0000605-201105030-00002.pdf","trainingLevel":"Fellow","citation":"Hanania, NA <i>et al</i>. \"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial\". <i>Annals of Internal Medicine</i>. 2011. 154(9):573-582.","subspecialties":"Allergy and Immunology;Pulmonology;Pediatrics","expansion":"A Study of Omalizumab/Xolair in Subjects With Moderate to Severe Persistent Asthma","briefResultsDescription":"Omalizumab reduces asthma exacerbations","published":"2011-05-03","pageName":"EXTRA","diseases":"Asthma","abbreviation":"EXTRA","title":"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial","pmid":"21536936"},{"timestamp":"2013-06-18T14:58:27Z","briefDesignDescription":"Fluid management in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa062200","pageid":24,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa062200","trainingLevel":"Resident\n}}","citation":"Wiedemann HP, <i>et al</i>. \"Comparison of two fluid-management strategies in acute lung injury\". <i>The New England Journal of Medicine</i>. 2006. 354(24):2564-75.","subspecialties":"Critical Care","expansion":"Fluids and Catheters Treatment Trial","briefResultsDescription":"Mortality benefit of conservative fluid management in ALI/ARDS","published":"2006-06-15","pageName":"FACTT","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"FACTT","title":"Comparison of two fluid-management strategies in acute lung injury","pmid":"16714767"},{"timestamp":"2013-02-20T06:44:13Z","briefDesignDescription":"FFR-guided PCI in stable CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807611","pageid":998,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807611","trainingLevel":"resident","citation":"Tonino PAL, <i>et al</i>. \"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention\". <i>The New England Journal of Medicine</i>. 2009. 360(3):213-224.","subspecialties":"Cardiology","expansion":"Fractional Flow Reserve versus Angiography for Multivessel Evaluation","briefResultsDescription":"FFR reduces composite of death, nonfatal MI, urgent revascularization","published":"2009-01-15","pageName":"FAME","diseases":"Coronary Artery Disease","abbreviation":"FAME","title":"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention","pmid":"19144937"},{"timestamp":"2014-10-07T16:18:34Z","briefDesignDescription":"FFR-guided PCI vs. OMT in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1205361","pageid":1003,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205361","trainingLevel":"Resident","citation":"De Bruyne B, <i>et al</i>. \"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease\". <i>The New England Journal of Medicine</i>. 2012. 367(11):991-1001.","subspecialties":"Cardiology","expansion":"FFR vs. Angiographyfor Multivessel Evaluation 2","briefResultsDescription":"FFR-guided PCI reduces urgent revascularization","published":"2012-09-13","pageName":"FAME 2","diseases":"Coronary Artery Disease","abbreviation":"FAME 2","title":"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease","pmid":"22924638"},{"timestamp":"2014-11-28T20:04:58Z","briefDesignDescription":"Fluid resuscitation in Sub-Saharan Africa","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1101549","pageid":1860,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1101549","trainingLevel":"Resident","citation":"Maitland K, <i>et al</i>. \"Mortality after fluid bolus in African children with severe infection\". <i>The New England Journal of Medicine</i>. 2011. 364(26):2483-2495.","subspecialties":"Pediatrics;Critical Care","expansion":"Fluid Expansion as Supportive Therapy","briefResultsDescription":"Albumin and saline increase mortality when compared to no fluids in this patient population","published":"2011-06-30","pageName":"FEAST","diseases":"Shock","abbreviation":"FEAST","title":"Mortality after fluid bolus in African children with severe infection","pmid":"21615299"},{"timestamp":"2013-10-07T20:50:13Z","briefDesignDescription":"Fidaxomicin in C. difficile","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0910812","pageid":255,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812","trainingLevel":"Resident","citation":"Louie TJ, <i>et al</i>. \"Fidaxomicin versus Vancomycin for Clostridium difficile Infection\". <i>The New England Journal of Medicine</i>. 2011. 365(5):422-431.","subspecialties":"Infectious Disease;Gastroenterology","expansion":null,"briefResultsDescription":"Fidaxomicin noninferior to vancomycin for cure, and resulted in 45% fewer recurrences","published":"2011-02-03","pageName":"Fidaxomicin in C. difficile Diarrhea","diseases":"Clostridium difficile","abbreviation":null,"title":"Fidaxomicin versus Vancomycin for Clostridium difficile Infection","pmid":"21288078"},{"timestamp":"2013-10-05T21:06:06Z","briefDesignDescription":"Risk factors for GI bleeds in ICU patients","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199402103300601","pageid":391,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199402103300601","trainingLevel":"Intern","citation":"Cook DJ, <i>et al</i>. \"Risk factors for gastrointestinal bleeding in critically ill patients\". <i>The New England Journal of Medicine</i>. 1994. 330(6):337-381.","subspecialties":"Critical Care;Gastroenterology","expansion":null,"briefResultsDescription":"Greatest risk for GI bleed with coagulopathy and mechanical ventilation","published":"1994-02-10","pageName":"GI bleeding in ICU patients","diseases":"Gastrointestinal Hemorrhage","abbreviation":null,"title":"Risk factors for gastrointestinal bleeding in critically ill patients","pmid":"8284001"},{"timestamp":"2014-09-24T22:28:37Z","briefDesignDescription":"Lisinopril in acute MI","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract","pageid":258,"pdfurl":"","trainingLevel":"Resident\n}}","citation":"GISSI-3 Group. \"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction\". <i>The Lancet</i>. 1994. 343(8906):1115-22.","subspecialties":"Cardiology","expansion":"Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico","briefResultsDescription":"Lisinopril improves 6-week mortality","published":"1994-05-07","pageName":"GISSI-3","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"GISSI-3","title":"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction","pmid":"7910229"},{"timestamp":"2014-09-25T10:35:44Z","briefDesignDescription":"tPA in ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199309023291001","pageid":2177,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199309023291001","trainingLevel":"Student\n}}","citation":"Topol E, <i>et al</i>. \"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 1993. 329(10):673-682.","subspecialties":"Cardiology","expansion":"Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries","briefResultsDescription":"tPA reduces mortality in ACS","published":"1993-09-03","pageName":"GUSTO","diseases":"Myocardial Infarction;Acute Coronary Syndrome","abbreviation":"GUSTO","title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","pmid":"8204123"},{"timestamp":"2014-09-19T10:30:21Z","briefDesignDescription":"Hypothermia for cardiac arrest","fulltexturl":"http://www.nejm.org/doi/full/10.1056/nejmoa012689","pageid":410,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/nejmoa012689","trainingLevel":"Resident","citation":"Holzer M, <i>et al</i>. \"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2002. 346(8):549-556.","subspecialties":"Critical Care;Neurology;Cardiology","expansion":"Hypothermia After Cardiac Arrest","briefResultsDescription":"Hypothermia improves neurologic outcomes and reduces mortality","published":"2002-02-21","pageName":"HACA","diseases":"Cardiac Arrest","abbreviation":"HACA","title":"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest","pmid":"11856793"},{"timestamp":"2013-10-09T17:11:02Z","briefDesignDescription":"Trastuzumab in breast cancer","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052306","pageid":440,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052306","trainingLevel":"Resident","citation":"Piccart-Gebhart MJ, <i>et al</i>. \"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer\". <i>The New England Journal of Medicine</i>. 2005. 353(16):1659-72.","subspecialties":"Oncology","expansion":"Herceptin Adjuvant Trial","briefResultsDescription":"Trastuzumab improves survival","published":"2005-10-20","pageName":"HERA","diseases":"Breast Cancer","abbreviation":"HERA","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","pmid":"16236737"},{"timestamp":"2013-08-15T18:50:04Z","briefDesignDescription":"Ramipril in patients with high CV risk","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200001203420301","pageid":1165,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200001203420301","trainingLevel":"intern","citation":"Yusuf S, <i>et al</i>. \"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients\". <i>The New England Journal of Medicine</i>. 2000. 342(3):145-153.","subspecialties":"Cardiology;Neurology","expansion":"Heart Outcomes Prevention Evaluation","briefResultsDescription":"Ramipril reduces death, MI, and stroke","published":"2000-01-20","pageName":"HOPE","diseases":"Coronary Artery Disease;Stroke;Transient Ischemic Attack","abbreviation":"HOPE","title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","pmid":"10639539"},{"timestamp":"2014-11-24T14:57:45Z","briefDesignDescription":"Early ART in HIV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1105243","pageid":1010,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243","trainingLevel":"Resident\n}}","citation":"Cohen MS, <i>et al</i>. \"Prevention of HIV-1 Infection with Early Antiretroviral Therapy\". <i>The New England Journal of Medicine</i>. 2011. 365(6):493-505.","subspecialties":"Infectious Disease","expansion":"HIV Prevention Trials Network 052 Study","briefResultsDescription":"Reduced morbidity and HIV transmission","published":"2011-08-11","pageName":"HPTN 052","diseases":"HIV","abbreviation":"HPTN 052","title":"Prevention of HIV-1 Infection with Early Antiretroviral Therapy","pmid":"21767103"},{"timestamp":"2014-12-05T14:52:27Z","briefDesignDescription":"Perinatal vitamins to prevent neural tube defects","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199212243272602","pageid":2142,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199212243272602","trainingLevel":"Student","citation":"Czeizel AE and Dudas I. \"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation\". <i>The New England Journal of Medicine</i>. 1992. 327(26):1832-1835.","subspecialties":"Obstetrics;Preventive Medicine","expansion":null,"briefResultsDescription":"Perinatal vitamins reduce neural tube defects","published":"1992-12-24","pageName":"Hungarian Prenatal Vitamin Trial","diseases":"Neural Tube Defects","abbreviation":null,"title":"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation","pmid":"1307234"},{"timestamp":"2014-06-13T05:59:23Z","briefDesignDescription":"IABP in MI and cardiogenic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208410","pageid":1065,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208410","trainingLevel":"Fellow","citation":"Thiele H, <i>et al</i>. \"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 2012. 367(14):1287-1296.","subspecialties":"Cardiology;Critical Care","expansion":"Intraaortic Balloon Pump in Cardiogenic Shock II","briefResultsDescription":"IABP did not reduce mortality at 30 days","published":"2012-10-10","pageName":"IABP-SHOCK II","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Shock","abbreviation":"IABP-SHOCK II","title":"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock","pmid":"22920912"},{"timestamp":"2014-05-19T00:18:23Z","briefDesignDescription":"Colchicine in the first episode of acute pericarditis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208536","pageid":1729,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208536","trainingLevel":"Intern","citation":"Imazio M, <i>et al</i>. \"A Randomized Trial of Colchicine for Acute Pericarditis\". <i>The New England Journal of Medicine</i>. 2013. 369(16):1522-1528.","subspecialties":"Cardiology","expansion":"Evaluation of additive benefit of colchicine to conventional therapy in acute pericarditis","briefResultsDescription":"Colchicine reduces incessant or recurrent acute pericarditis when used in first episode","published":"2013-10-17","pageName":"ICAP","diseases":"Acute Pericarditis","abbreviation":"ICAP","title":"A Randomized Trial of Colchicine for Acute Pericarditis","pmid":"23992557"},{"timestamp":"2013-03-05T21:36:40Z","briefDesignDescription":"Early vs. late dialysis in CKD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1000552","pageid":1020,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000552","trainingLevel":"Resident","citation":"Cooper BA, <i>et al</i>. \"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis\". <i>The New England Journal of Medicine</i>. 2010. 363(7):609-619.","subspecialties":"Nephrology","expansion":"Initiating Dialysis Early and Late","briefResultsDescription":"No difference in survival or clinical outcomes","published":"2010-08-12","pageName":"IDEAL","diseases":"Chronic Kidney Disease","abbreviation":"IDEAL","title":"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis","pmid":"20581422"},{"timestamp":"2014-12-05T14:51:11Z","briefDesignDescription":"ART in primary HIV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1011205","pageid":1100,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011205","trainingLevel":"intern","citation":"Grant RM, <i>et al</i>. \"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men\". <i>The New England Journal of Medicine</i>. 2010. 363(27):2587-2599.","subspecialties":"Infectious Disease;Preventive Medicine","expansion":"Iniciativa Profilaxis Pre Exposicion (\"Preexposure Prophylaxis Initiative\")","briefResultsDescription":"ART reduces tranmission of HIV among MSM","published":"2010-12-30","pageName":"IPrEx","diseases":"HIV","abbreviation":"iPrEx","title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","pmid":"21091279"},{"timestamp":"2013-08-07T13:43:06Z","briefDesignDescription":"Imatinib vs. IFNα/cytarabine in CML","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa022457","pageid":1076,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa022457","trainingLevel":"Student","citation":"O'Brien SG, <i>et al</i>. \"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia\". <i>The New England Journal of Medicine</i>. 2003. 384(11):994-1004.","subspecialties":"Hematology;Oncology","expansion":"International Randomized Study of Interferon and STI571","briefResultsDescription":"Imatinib delays disease progression","published":"2003-03-13","pageName":"IRIS","diseases":"Chronic Myeloid Leukemia","abbreviation":"IRIS","title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","pmid":"12637609"},{"timestamp":"2014-09-26T17:54:13Z","briefDesignDescription":"Aspirin ± streptokinase in acute MI","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)92833-4/abstract","pageid":133,"pdfurl":"","trainingLevel":"Resident\n}}","citation":"ISIS-2 Collaborative Group. \"Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction\". <i>The Lancet</i>. 1988. 332(8607):349-360.","subspecialties":"Cardiology","expansion":"Second International Study of Infarct Survival","briefResultsDescription":"Mortality benefit of aspirin within 24 hours of acute MI","published":"1988-08-13","pageName":"ISIS-2","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"ISIS-2","title":"Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction","pmid":"2899772"},{"timestamp":"2014-06-23T04:32:06Z","briefDesignDescription":"Aspirin in acute ischemic stroke","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)04011-7/fulltext","pageid":132,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673697040117.pdf","trainingLevel":"Intern","citation":"IST Collaborative Group. \"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke\". <i>The Lancet</i>. 1997. 349(9065):1569-1581.","subspecialties":"Neurology","expansion":"International Stroke Trial","briefResultsDescription":"Mortality benefit with aspirin","published":"1997-05-31","pageName":"IST","diseases":"Stroke","abbreviation":"IST","title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke","pmid":"9174558"},{"timestamp":"2014-12-05T14:50:01Z","briefDesignDescription":"Rosuvastatin for primary CV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807646","pageid":445,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807646","trainingLevel":"resident","citation":"Ridker PM, <i>et al</i>. \"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein\". <i>The New England Journal of Medicine</i>. 2008. 359(21):2195-2207.","subspecialties":"Cardiology;Preventive Medicine","expansion":"Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin","briefResultsDescription":"Rosuvastatin delays major CV events","published":"2008-11-20","pageName":"JUPITER","diseases":"Hyperlipidemia;Coronary Artery Disease;Stroke;Transient Ischemic Attack","abbreviation":"JUPITER","title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","pmid":"18997196"},{"timestamp":"2014-09-13T02:02:58Z","briefDesignDescription":"Epidural steroids in spinal stenosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1313265","pageid":1883,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313265","trainingLevel":"Resident\n}}","citation":"Friedly JL, <i>et al</i>. \"A randomized trial of epidural glucocorticoid injections for spinal stenosis\". <i>The New England Journal of Medicine</i>. 2014. 371(1):11-21.","subspecialties":"Anesthesiology;Physical Medicine and Rehabilitation;Radiology","expansion":"Lumbar Epidural Steroid Injections for Spinal Stenosis","briefResultsDescription":"Epidural steroids don't improve pain or disability at six weeks","published":"2014-07-03","pageName":"LESS","diseases":"Spinal Stenosis","abbreviation":"LESS","title":"A randomized trial of epidural glucocorticoid injections for spinal stenosis","pmid":"24988555"},{"timestamp":"2013-07-07T09:48:01Z","briefDesignDescription":"Intensive glycemic therapy in SICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011300","pageid":139,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011300","trainingLevel":"Resident","citation":"Van den Berghe G, <i>et al</i>. \"Intensive Insulin Therapy in Critically Ill Patients\". <i>The New England Journal of Medicine</i>. 2001. 345(19):1359-1367.","subspecialties":"Critical Care;Endocrinology","expansion":"","briefResultsDescription":"Intensive glycemic control reduces mortality","published":"2001-11-08","pageName":"Leuven Surgical Trial","diseases":"Stress Hyperglycemia","abbreviation":"Leuven Surgical Trial","title":"Intensive Insulin Therapy in Critically Ill Patients","pmid":"11794168"},{"timestamp":"2013-10-20T05:06:48Z","briefDesignDescription":"Colchicine for stable CAD","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0735109712054782","pageid":1583,"pdfurl":null,"trainingLevel":"Resident\n}}\n<!-- \nThe journal website has an equal sign as part of the URL, have to leave the sciencedirect version up for now until we can get the equal sign to be handled by our bot: http://content.onlinejacc.org/article.aspx?articleid","citation":"Nidorf SM, <i>et al</i>. \"Low-dose colchicine for secondary prevention of cardiovascular disease\". <i>Journal of the American College of Cardiology</i>. 2013. 61(4):404-410.","subspecialties":"Cardiology","expansion":"Low-Dose Colchicine","briefResultsDescription":"Colcicine may reduce complications in stable CAD","published":"2013-01-29","pageName":"LoDoCo","diseases":"Coronary Artery Disease","abbreviation":"LoDoCo","title":"Low-dose colchicine for secondary prevention of cardiovascular disease","pmid":"23265346"},{"timestamp":"2013-09-18T11:13:42Z","briefDesignDescription":"Weight loss and exercise in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1212914","pageid":1546,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212914","trainingLevel":"Intern","citation":"Wing RR, <i>et al</i>. \"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2013. 369(2):145-154.","subspecialties":"Endocrinology;Cardiology","expansion":"Look Action for HEAlth in Diabetes","briefResultsDescription":"No reduction of CVD with weight loss and exercise in T2DM","published":"2013-07-11","pageName":"Look AHEAD","diseases":"Diabetes Mellitus;Cardiovascular Disease","abbreviation":"Look AHEAD","title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","pmid":"23796131"},{"timestamp":"2014-06-13T06:00:39Z","briefDesignDescription":"CRT in HFrEF with QRS ≥130 msec and mild symptoms","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0906431","pageid":1780,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906431","trainingLevel":"Resident\n}}","citation":"Moss AJ, <i>et al</i>. \"Cardiac-resynchronization therapy for the prevention of heart-failure events\". <i>The New England Journal of Medicine</i>. 2009. 361(14):1329-1338.","subspecialties":"Cardiology","expansion":"Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy","briefResultsDescription":"CRT reduces mortality or HF complications in mildly symptomatic HFrEF with prolonged QRS","published":"2009-10-01","pageName":"MADIT-CRT","diseases":"Heart Failure","abbreviation":"MADIT-CRT","title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","pmid":"19723701"},{"timestamp":"2014-06-13T06:03:11Z","briefDesignDescription":"ICD in post-MI patients with HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa013474","pageid":385,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa013474","trainingLevel":"Resident\n}}","citation":"Moss AJ, <i>et al</i>. \"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction\". <i>The New England Journal of Medicine</i>. 2002. 346(12):877-883.","subspecialties":"Cardiology","expansion":"Multicenter Automatic Defibrillator Implantation Trial II","briefResultsDescription":"ICD improves survival in post-MI patients with LVEF≤30%","published":"2002-03-21","pageName":"MADIT-II","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"MADIT-II","title":"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction","pmid":"11907286"},{"timestamp":"2013-11-21T21:03:58Z","briefDesignDescription":"Rivaroxaban vs. LMWH for VTE prophylaxis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1111096","pageid":1272,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1111096","trainingLevel":"Resident\n}}","citation":"Cohen AT, <i>et al</i>. \"Rivaroxaban for thromboprophylaxis in acutely ill medical patients\". <i>The New England Journal of Medicine</i>. 2013. 368(6):513-523.","subspecialties":"Hematology","expansion":"Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin","briefResultsDescription":"Rivaroxaban similar to LMWH for prophylaxis, caused more bleeding","published":"2013-02-07","pageName":"MAGELLAN","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","abbreviation":"MAGELLAN","title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","pmid":"23388003"},{"timestamp":"2013-07-08T23:04:34Z","briefDesignDescription":"ASA/clopidogrel vs. clopidogrel in stroke","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16721-4/fulltext","pageid":1125,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673604167214.pdf","trainingLevel":"student","citation":"Diener HC, <i>et al</i>. \"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial\". <i>The Lancet</i>. 2004. 364(9431):331-337.","subspecialties":"Neurology","expansion":"Management of Atherothrombosis with Clopidogrel in High-risk patients","briefResultsDescription":"More major bleeding but no greater efficacy with combination therapy","published":"2004-07-24","pageName":"MATCH","diseases":"Stroke","abbreviation":"MATCH","title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","pmid":"15276392"},{"timestamp":"2014-06-13T06:05:38Z","briefDesignDescription":"Metoprolol in HFrEF","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140673699044402","pageid":130,"pdfurl":"","trainingLevel":"Resident\n}}","citation":"Fagerberg B, <i>et al</i>. \"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure\". <i>The Lancet</i>. 1999. 353(9169):2001-7.","subspecialties":"Cardiology","expansion":"Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure","briefResultsDescription":"Metoprolol improves survival in NYHA II-IV HFrEF","published":"1999-06-12","pageName":"MERIT-HF","diseases":"Heart Failure","abbreviation":"MERIT-HF","title":"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure","pmid":"10376614"},{"timestamp":"2013-10-20T05:06:34Z","briefDesignDescription":"Surgery vs. PT in OA with meniscal tear","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1301408","pageid":1429,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301408","trainingLevel":"Student\n}}","citation":"Katz JN, <i>et al</i>. \"Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis\". <i>The New England Journal of Medicine</i>. 2013. 368(18):1675-1684.","subspecialties":"Surgery;Physical Medicine and Rehabilitation","expansion":"Meniscal Tear in Osteoarthritis Research","briefResultsDescription":"Surgery no better than PT alone","published":"2013-05-02","pageName":"METEOR","diseases":"Meniscal Tear;Osteoarthritis","abbreviation":"METEOR","title":"Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis","pmid":"23506518"},{"timestamp":"2014-05-16T18:12:22Z","briefDesignDescription":"Early surgery for MR","fulltexturl":"","pageid":1787,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/927436/joi130034.pdf","trainingLevel":"Resident","citation":"Suri RM, <i>et al</i>. \"Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets\". <i>JAMA</i>. 2013. 310(6):609-616.","subspecialties":"Cardiology","expansion":"Mitral Regurgitation International Database","briefResultsDescription":"Early surgery reduces mortality in MR","published":"2013-08-14","pageName":"MIDA","diseases":"Mitral Regurgitation","abbreviation":"MIDA","title":"Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets","pmid":"23942679"},{"timestamp":"2014-09-24T22:10:56Z","briefDesignDescription":"Atorvastatin in UA/NSTEMI","fulltexturl":"http://jama.ama-assn.org/content/285/13/1711.long","pageid":432,"pdfurl":"http://jama.ama-assn.org/content/285/13/1711.full.pdf","trainingLevel":"Resident\n}}","citation":"Schwartz GG, <i>et al</i>. \"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes\". <i>Journal of the American Medical Association</i>. 2001. 285(13):1711-1718.","subspecialties":"Cardiology","expansion":"Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering","briefResultsDescription":"Atorvastatin reduced rate of CV events after UA/NSTEMI","published":"2001-04-04","pageName":"MIRACL","diseases":"Coronary Artery Disease;Acute Coronary Syndrome;Hyperlipidemia","abbreviation":"MIRACL","title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes","pmid":"11277825"},{"timestamp":"2014-06-25T15:05:10Z","briefDesignDescription":"Low-dose tPA for submassive PE","fulltexturl":"http://www.ajconline.org/article/S0002-9149%2812%2902205-9/fulltext","pageid":1785,"pdfurl":"http://download.journals.elsevierhealth.com/pdfs/journals/0002-9149/PIIS0002914912022059.pdf","trainingLevel":"Intern\n}}","citation":"Sharifi M, <i>et al</i>. \"Moderate pulmonary embolism treated with thrombolysis\". <i>The American Journal of Cardiology</i>. 2013. 111(2):273-277.","subspecialties":"Critical Care;Pulmonology;Cardiology","expansion":"Moderate Pulmonary Embolism Treated with Thrombolysis","briefResultsDescription":"Low-dose tPA reduces pulmonary HTN in submassive PE","published":"2013-01-15","pageName":"MOPETT","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"MOPETT","title":"Moderate pulmonary embolism treated with thrombolysis","pmid":"23102885"},{"timestamp":"2014-06-08T03:15:16Z","briefDesignDescription":"Arthroscopy in knee OA","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa013259","pageid":1055,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa013259","trainingLevel":"Resident","citation":"Moseley JB, <i>et al</i>. \"A controlled trial of arthroscopic surgery for osteoarthritis of the knee\". <i>The New England Journal of Medicine</i>. 2002. 347(2):81-88.","subspecialties":"Surgery;Physical Medicine and Rehabilitation","expansion":"","briefResultsDescription":"No difference between groups at 2 years","published":"2002-07-11","pageName":"Moseley Trial","diseases":"Osteoarthritis","abbreviation":"","title":"A controlled trial of arthroscopic surgery for osteoarthritis of the knee","pmid":"12110735"},{"timestamp":"2014-11-24T14:58:47Z","briefDesignDescription":"Early vs. delayed ART in HIV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807252","pageid":1039,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807252","trainingLevel":"Resident\n}}","citation":"Kitahata, MM <i>et al</i>. \"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival\". <i>The New England Journal of Medicine</i>. 2009. 360(18):1815-1826.","subspecialties":"Infectious Disease","expansion":"North American AIDS Cohort Collaboration on Research and Design","briefResultsDescription":"Early ART in HIV improves survival","published":"2009-04-30","pageName":"NA-ACCORD","diseases":"HIV","abbreviation":"NA-ACCORD","title":"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival","pmid":"19339714"},{"timestamp":"2013-04-16T20:36:00Z","briefDesignDescription":"CEA in symptomatic carotid stenosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199811123392002","pageid":128,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199811123392002","trainingLevel":"Intern","citation":"Barnett HJ, <i>et al</i>. \"Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis\". <i>The New England Journal of Medicine</i>. 1998. 339(20):1415-25.","subspecialties":"Surgery;Neurology","expansion":"North American Symptomatic Carotid Endarterectomy Trial","briefResultsDescription":"CEA reduces the risk of death or stroke in symptomatic 50-69% carotid stenosis","published":"1998-11-12","pageName":"NASCET","diseases":"Carotid Stenosis;Stroke","abbreviation":"NASCET","title":"Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis","pmid":"9811916"},{"timestamp":"2013-07-01T16:53:38Z","briefDesignDescription":"Dialysis prescriptions in ESRD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198111123052003","pageid":504,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198111123052003","trainingLevel":"Fellow","citation":"Lowrie EG, <i>et al</i>. \"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study\". <i>The New England Journal of Medicine</i>. 1981. 305(20):1176-1181.","subspecialties":"Nephrology","expansion":"The National Cooperative Dialysis Study","briefResultsDescription":"Low BUN better tolerated, fewer hospitalizations","published":"1981-11-12","pageName":"NCDS","diseases":"Chronic Kidney Disease","abbreviation":"NCDS","title":"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study","pmid":"7027040"},{"timestamp":"2014-09-29T20:08:35Z","briefDesignDescription":"Lung volume reduction in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030287","pageid":1604,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030287","trainingLevel":"Resident","citation":"Fishman A, <i>et al</i>. \"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema\". <i>The New England Journal of Medicine</i>. 2003. 348(21):2059-2073.","subspecialties":"Surgery;Pulmonology","expansion":"National Emphysema Treatment Trial","briefResultsDescription":"LVRS benefits apical emphysema and those with low exercise function","published":"2003-05-22","pageName":"NETT","diseases":"Chronic Obstructive Pulmonary Disease;Emphysema","abbreviation":"NETT","title":"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema","pmid":"12759479"},{"timestamp":"2014-07-03T23:47:32Z","briefDesignDescription":"Intensive glycemic therapy in ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0810625","pageid":26,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810625","trainingLevel":"Intern","citation":"Finfer S, <i>et al</i>. \"Intensive versus conventional glucose control in critically ill patients\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1283-1297.","subspecialties":"Critical Care;Endocrinology","expansion":"Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation","briefResultsDescription":"Increased mortality targeting euglycemia","published":"2009-03-26","pageName":"NICE-SUGAR","diseases":"Stress Hyperglycemia","abbreviation":"NICE-SUGAR","title":"Intensive versus conventional glucose control in critically ill patients","pmid":"19318384"},{"timestamp":"2013-06-17T12:56:04Z","briefDesignDescription":"tPA in ischemic stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199512143332401","pageid":131,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199512143332401","trainingLevel":"MedicalStudent","citation":"Marler JR, <i>et al</i>. \"Tissue Plasminogen Activator for Acute Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 1995. 333(24):1581-1587.","subspecialties":"Neurology;Critical Care","expansion":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study","briefResultsDescription":"tPA within 3 hours improved outcomes","published":"1995-12-14","pageName":"NINDS","diseases":"Stroke","abbreviation":"NINDS","title":"Tissue Plasminogen Activator for Acute Ischemic Stroke","pmid":"7477192"},{"timestamp":"2014-12-05T14:53:58Z","briefDesignDescription":"CT vs. CXR in lung cancer screening","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1102873","pageid":980,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102873","trainingLevel":"Resident","citation":"Berg CD, <i>et al</i>. \"Reduced lung cancer mortality with low-dose computed tomographic screening\". <i>The New England Journal of Medicine</i>. 2011. 365(5):395-409.","subspecialties":"Pulmonology;Oncology;Preventive Medicine","expansion":"National Lung Screening Trial","briefResultsDescription":"Low-dose CT reduces lung cancer mortality compared to CXR","published":"2011-08-04","pageName":"NLST","diseases":"Lung Cancer","abbreviation":"NLST","title":"Reduced lung cancer mortality with low-dose computed tomographic screening","pmid":"21714641"},{"timestamp":"2014-07-24T19:49:48Z","briefDesignDescription":"Continuous vs. nocturnal oxygen in COPD","fulltexturl":"http://annals.org/article.aspx?articleid","pageid":1788,"pdfurl":"","trainingLevel":"Student","citation":"NOTT Group. \"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group\". <i>Annals of Internal Medicine</i>. 1980. 93(3):91-398.","subspecialties":"Pulmonology","expansion":"Nocturnal Oxygen Therapy Trial","briefResultsDescription":"Continuous oxygen reduces mortality in COPD with hypoxemia","published":"1980-09-01","pageName":"NOTT","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"NOTT","title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group","pmid":"6776858"},{"timestamp":"2013-03-12T08:34:38Z","briefDesignDescription":"Sentinel LN biopsy in breast cancer","fulltexturl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/","pageid":1167,"pdfurl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/pdf/nihms-250175.pdf","trainingLevel":"Student","citation":"Krag DN, <i>et al</i>. \"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial\". <i>Lancet Oncology</i>. 2010. 11(10):927-933.","subspecialties":"Oncology","expansion":"National Surgical Adjuvant Breast and Bowel Project Trial B-32","briefResultsDescription":"Sentinel lymph node biopsy is equally efficacious but has fewer side effects than ALND","published":"2010-10-01","pageName":"NSABP B-32","diseases":"Breast Cancer","abbreviation":"NSABP B-32","title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","pmid":"20863759"},{"timestamp":"2014-12-05T14:53:26Z","briefDesignDescription":"Tamoxifen in breast cancer prevention","fulltexturl":"http://jnci.oxfordjournals.org/content/90/18/1371.long","pageid":1049,"pdfurl":"http://jnci.oxfordjournals.org/content/90/18/1371.full.pdf+html","trainingLevel":"resident\n}}","citation":"Fisher B, <i>et al</i>. \"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study\". <i>Journal of the National Cancer Institute</i>. 1998. 90(18):1371-1388.","subspecialties":"Oncology;Preventive Medicine","expansion":"National Surgical Adjuvant Breast and Bowel Project, Prevention-1","briefResultsDescription":"Tamoxifen reduces breast cancer incidence by 48%","published":"1998-09-16","pageName":"NSABP P-1","diseases":"Breast Cancer","abbreviation":"NSABP P-1","title":"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","pmid":"9747868"},{"timestamp":"2012-04-26T00:18:57Z","briefDesignDescription":"IV PPI for GI bleeds","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200008033430501","pageid":247,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200008033430501","trainingLevel":"Resident","citation":"Lau JYW, <i>et al</i>. \"Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer\". <i>The New England Journal of Medicine</i>. 2000. 343(5):310-316.","subspecialties":"Gastroenterology","expansion":null,"briefResultsDescription":"IV omeprazole reduced 30-day rebleeding","published":"2000-08-03","pageName":"Omeprazole in Peptic Ulcer Bleeding","diseases":"Gastrointestinal Hemorrhage","abbreviation":null,"title":"Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer","pmid":"10922420"},{"timestamp":"2014-08-11T16:05:12Z","briefDesignDescription":"Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0801317","pageid":1776,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801317","trainingLevel":"Resident \n}}","citation":"Yusuf S, <i>et al</i>. \"Telmisartan, ramipril, or both in patients at high risk for vascular events\". <i>The New England Journal of Medicine</i>. 2008. 358(15):1547-1559.","subspecialties":"Cardiology;Nephrology;Endocrinology","expansion":"Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial","briefResultsDescription":"No difference in CV complications, combination ACE-inhibitor and ARB poorly tolerated","published":"2008-04-10","pageName":"ONTARGET","diseases":"Cardiovascular Disease;Diabetes Mellitus;Stroke","abbreviation":"ONTARGET","title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","pmid":"18378520"},{"timestamp":"2014-06-20T20:23:54Z","briefDesignDescription":"ASA/warfarin vs. warfarin in AF","fulltexturl":"http://circ.ahajournals.org/content/128/7/721.long","pageid":1769,"pdfurl":"http://circ.ahajournals.org/content/128/7/721.full.pdf","trainingLevel":"Fellow","citation":"Steinberg BA, <i>et al</i>. \"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry\". <i>Circulation</i>. 2013. 128(7):721-8.","subspecialties":"Cardiology;Neurology","expansion":"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation","briefResultsDescription":"ASA/warfarin associated with more bleeding, fewer CV events","published":"2013-08-13","pageName":"ORBIT-AF","diseases":"Atrial Fibrillation;Stroke","abbreviation":"ORBIT-AF","title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry","pmid":"23861512"},{"timestamp":"2013-10-20T05:06:18Z","briefDesignDescription":"High-frequency oscillatory vent in early ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1215554","pageid":1254,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215554","trainingLevel":"Resident\n}}","citation":"Ferguson ND, <i>et al</i>. \"High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome\". <i>The New England Journal of Medicine</i>. 2013. 368(9):795-805.","subspecialties":"Critical Care;Pulmonology","expansion":"Oscillation for Acute Respiratory Distress Syndrome Treated Early","briefResultsDescription":"High-frequency oscillatory vent may harm in early ARDS","published":"2013-02-28","pageName":"OSCILLATE","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"Oscillate","title":"High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome","pmid":"23339639"},{"timestamp":"2012-11-11T16:21:51Z","briefDesignDescription":"Step-up approach to pancreatitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0908821","pageid":398,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0908821","trainingLevel":"Fellow","citation":"van Santvoort HC, <i>et al</i>. \"A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis\". <i>The New England Journal of Medicine</i>. 2010. 362(16):1491-502.","subspecialties":"Surgery;Gastroenterology","expansion":"Minimally Invasive Step Up Approach versus Maximal Necrosectomy in Patients with Acute Necrotising Pancreatitis","briefResultsDescription":"Step-up approach reduces major complications and death","published":"2010-04-22","pageName":"PANTER","diseases":"Pancreatitis","abbreviation":"PANTER","title":"A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis","pmid":"20410514"},{"timestamp":"2014-09-22T13:23:01Z","briefDesignDescription":"ARNI vs. enalapril in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1409077","pageid":2163,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409077","trainingLevel":"Resident\n}}","citation":"McMurray JJV, <i>et al</i>. \"Angiotensin-neprilysin inhibition versus enalapril in heart failure\". <i>The New England Journal of Medicine</i>. 2014. 371(11):993-1004.","subspecialties":"Cardiology","expansion":"Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure","briefResultsDescription":"ARNI reduces mortality in HFrEF","published":"2014-08-30","pageName":"PARADIGM-HF","diseases":"Heart Failure","abbreviation":"PARADIGM-HF","title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","pmid":"25176015"},{"timestamp":"2014-05-11T22:03:58Z","briefDesignDescription":"Maintenance pemetrexed in lung cancer","fulltexturl":"http://jco.ascopubs.org/content/31/23/2895.long","pageid":1606,"pdfurl":"http://jco.ascopubs.org/content/31/23/2895.full.pdf","trainingLevel":"Fellow","citation":"Paz-Ares LG, <i>et al</i>. \"PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer\". <i>Journal of Clinical Oncology</i>. 2013. 31(23):2895-902.","subspecialties":"Oncology","expansion":"","briefResultsDescription":"Maintenance pemetrexed improves PFS and OS following induction with cisplatin/pemetrexed","published":"2013-08-10","pageName":"PARAMOUNT","diseases":"Lung Cancer","abbreviation":"PARAMOUNT","title":"PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer","pmid":"23835707"},{"timestamp":"2014-05-11T18:52:23Z","briefDesignDescription":"TAVI for AS in poor surgical candidates","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1008232","pageid":1674,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008232","trainingLevel":"Intern","citation":"Leon MB, <i>et al</i>. \"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery\". <i>The New England Journal of Medicine</i>. 2010. 363(17):1597-1607.","subspecialties":"Cardiology","expansion":"Placement of Aortic Transcatheter Valves, Cohort B","briefResultsDescription":"TAVI reduces all-cause mortality ± rehospitalization, increased stroke","published":"2010-10-21","pageName":"PARTNER B","diseases":"Aortic Stenosis","abbreviation":"PARTNER B","title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","pmid":"20961243"},{"timestamp":"2014-10-13T21:17:38Z","briefDesignDescription":"Finasteride for prostate cancer prophylaxis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030660","pageid":1786,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030660","trainingLevel":"Intern","citation":"Thompson IM, <i>et al</i>. \"The influence of finasteride on the development of prostate cancer\". <i>The New England Journal of Medicine</i>. 2003. 349(3):215-224.","subspecialties":"Urology;Oncology","expansion":"Prostate Cancer Prevention Trial","briefResultsDescription":"Finasteride reduces all-grade prostate cancer risk, increases high-grade disease","published":"2003-07-13","pageName":"PCPT","diseases":"Prostate Cancer","abbreviation":"PCPT","title":"The influence of finasteride on the development of prostate cancer","pmid":"12824459"},{"timestamp":"2014-06-02T23:09:30Z","briefDesignDescription":"tPA for submassive PE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1302097","pageid":1778,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302097","trainingLevel":"resident\n}}","citation":"Meyer G, <i>et al</i>. \"Fibrinolysis for patients with intermediate-risk pulmonary embolism\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1402-1411.","subspecialties":"Critical Care;Pulmonology;Hematology","expansion":"Pulmonary Embolism Thrombolysis trial","briefResultsDescription":"tPA reduces hemodynamic decomp, not mortality, also increases bleeding in submassive PE","published":"2014-04-10","pageName":"PEITHO","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"PEITHO","title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","pmid":"24716681"},{"timestamp":"2014-07-28T19:37:25Z","briefDesignDescription":"Pentoxifylline in alcoholic hepatitis","fulltexturl":"http://www.gastrojournal.org/article/S0016-5085(00)51183-4/fulltext","pageid":53,"pdfurl":"http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508500511834.pdf","trainingLevel":"Resident","citation":"Akriviadis E, <i>et al</i>. \"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial\". <i>Gastroenterology</i>. 2000. 119(6):1637-48.","subspecialties":"Gastroenterology","expansion":"","briefResultsDescription":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis","published":"2000-12-20","pageName":"Pentoxifylline in Severe Alcoholic Hepatitis","diseases":"Alcoholic Hepatitis","abbreviation":"","title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","pmid":"11113085"},{"timestamp":"2013-07-03T16:14:14Z","briefDesignDescription":"Accuracy of CT for PE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052367#t","pageid":161,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052367#t","trainingLevel":"MedicalStudent","citation":"Stein PD, <i>et al</i>. \"Multidetector Computed Tomography for Acute Pulmonary Embolism\". <i>The New England Journal of Medicine</i>. 2006. 354(22):2317-2327.","subspecialties":"Pulmonology;Hematology","expansion":"Prospective Investigation of Pulmonary Embolism Diagnosis II","briefResultsDescription":"CT sensitive and specific in detecting acute PE","published":"2006-06-01","pageName":"PIOPED II","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"PIOPED II","title":"Multidetector Computed Tomography for Acute Pulmonary Embolism","pmid":"16738268"},{"timestamp":"2014-12-05T14:51:49Z","briefDesignDescription":"Probiotics to prevent CDAD","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961218-0/abstract","pageid":1770,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673613612180.pdf","trainingLevel":"Resident\n}}","citation":"Allen SJ, <i>et al</i>. \"Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial\". <i>The Lancet</i>. 2013. 382(9900):1249-1257.","subspecialties":"Gastroenterology;Infectious Disease;Preventive Medicine","expansion":"","briefResultsDescription":"Probiotics do not reduce diarrhea including C. diff with antibiotics","published":"2013-10-12","pageName":"PLACIDE","diseases":"Clostridium difficile","abbreviation":"PLACIDE","title":"Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial","pmid":"23932219"},{"timestamp":"2014-09-26T17:58:39Z","briefDesignDescription":"Ticagrelor vs. clopidogrel in ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0904327","pageid":1629,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904327","trainingLevel":"Resident\n}}","citation":"Wallentin L, <i>et al</i>. \"Ticagrelor versus clopidogrel in patients with acute coronary syndromes\". <i>The New England Journal of Medicine</i>. 2009. 361(11):1045-1057.","subspecialties":"Cardiology","expansion":"Platelet Inhibition and Patient Outcomes","briefResultsDescription":"Ticagrelor reduces mortality, increases bleeding","published":"2009-09-10","pageName":"PLATO","diseases":"Acute Coronary Syndrome;Coronary Artery Disease","abbreviation":"PLATO","title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","pmid":"19717846"},{"timestamp":"2012-05-07T02:36:42Z","briefDesignDescription":"8 vs. 15 days of antibiotics in VAP","fulltexturl":"http://jama.ama-assn.org/content/290/19/2588.long","pageid":118,"pdfurl":"http://jama.ama-assn.org/content/290/19/2588.full.pdf","trainingLevel":"Intern","citation":"Chastre J. \"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial\". <i>Journal of the American Medical Association</i>. 2003. 290(19):2588-98.","subspecialties":"Critical Care;Infectious Disease;Pulmonology","expansion":"","briefResultsDescription":"8 days of antibiotics are equivalent to 15 days","published":"2003-11-19","pageName":"PneumA","diseases":"Pneumonia","abbreviation":"PneumA","title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","pmid":"14625336"},{"timestamp":"2014-10-17T07:39:25Z","briefDesignDescription":"Perioperative metoprolol","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60601-7/fulltext","pageid":173,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673608606017.pdf","trainingLevel":"Intern","citation":"Devereaux PJ, <i>et al</i>. \"Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial\". <i>The Lancet</i>. 2008. 371(9627):1839-1847.","subspecialties":"Surgery;Cardiology","expansion":"PeriOperative ISchemic Evaluation","briefResultsDescription":"Perioperative metoprolol reduces MI risk but increases risk of mortality and stroke","published":"2008-05-31","pageName":"POISE","diseases":"Cardiac Risk Assessment;Coronary Artery Disease","abbreviation":"POISE","title":"Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial","pmid":"18479744"},{"timestamp":"2014-08-04T17:37:26Z","briefDesignDescription":"Perioperative ASA","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1401105","pageid":1777,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401105","trainingLevel":"Intern","citation":"Devereaux PJ, <i>et al</i>. \"Aspirin in patients undergoing noncardiac surgery\". <i>The New England Journal of Medicine</i>. 2014. 370(16):1494-1503.","subspecialties":"Cardiology;Surgery","expansion":"Perioperative ischemic evaluation 2 aspirin arm","briefResultsDescription":"Perioperative ASA doesn't modify MI rates but increases major bleeding","published":"2014-03-31","pageName":"POISE-2 ASA","diseases":"Cardiac Risk Assessment","abbreviation":"POISE-2 ASA","title":"Aspirin in patients undergoing noncardiac surgery","pmid":"24679062"},{"timestamp":"2013-11-26T10:47:19Z","briefDesignDescription":"PCI to high-risk non-infarct arteries in STEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1305520","pageid":1748,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305520","trainingLevel":"Resident\n}}","citation":"Wald DS, <i>et al</i>. \"Randomized trial of preventative angioplasty in myocardial infarction\". <i>The New England Journal of Medicine</i>. 2013. 369(12):1115-1123.","subspecialties":"Cardiology","expansion":"Preventative Angioplasty in Acute Myocardial Infarction","briefResultsDescription":"PCI to high-risk non infarct arteries in STEMI improves CV outcomes","published":"2013-09-19","pageName":"PRAMI","diseases":"Myocardial Infarction","abbreviation":"PRAMI","title":"Randomized trial of preventative angioplasty in myocardial infarction","pmid":"23991625"},{"timestamp":"2014-09-19T15:33:46Z","briefDesignDescription":"Mediterranean diet in CVD prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200303","pageid":1247,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200303","trainingLevel":"Student","citation":"Estruch R, <i>et al</i>. \"Primary prevention of cardiovascular disease with a mediterranean diet\". <i>The New England Journal of Medicine</i>. 2013. 368(14):1279-1290.","subspecialties":"Cardiology","expansion":"Prevención con Dieta Mediterránea","briefResultsDescription":"Mediterranean diet reduces composite rate of MI/CVA/CV death","published":"2013-02-25","pageName":"PREDIMED","diseases":"Coronary Artery Disease;Stroke;Transient Ischemic Attack","abbreviation":"PREDIMED","title":"Primary prevention of cardiovascular disease with a mediterranean diet","pmid":"23432189"},{"timestamp":"2014-07-28T19:38:19Z","briefDesignDescription":"Prednisolone vs. placebo in alcoholic hepatitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199202203260802","pageid":1113,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199202203260802","trainingLevel":"Intern","citation":"Ramond MJ, <i>et al</i>. \"A randomized trial of prednisolone in patients with severe alcoholic hepatitis\". <i>The New England Journal of Medicine</i>. 1992. 362(8):507-512.","subspecialties":"Gastroenterology","expansion":"","briefResultsDescription":"Prednisolone improves short-term survival","published":"1992-02-20","pageName":"Prednisolone in Severe Alcoholic Hepatitis","diseases":"Alcoholic Hepatitis","abbreviation":"","title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis","pmid":"1531090"},{"timestamp":"2013-03-21T00:59:25Z","briefDesignDescription":"Rifapentine/isoniazid in latent TB","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1104875","pageid":928,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1104875","trainingLevel":"fellow","citation":"Sterling TR, <i>et al</i>. \"Three months of rifapentine and isoniazid for latent tuberculosis infection.\". <i>The New England Journal of Medicine</i>. 2011. 365(23):2155-66.","subspecialties":"Infectious Disease","expansion":null,"briefResultsDescription":"Rifapentine/isoniazid x3 months is noninferior to isoniazid x9 months","published":"2011-12-08","pageName":"PREVENT TB","diseases":"Tuberculosis","abbreviation":"PREVENT TB","title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","pmid":"22150035"},{"timestamp":"2014-10-01T18:05:46Z","briefDesignDescription":"EGDT in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1401602","pageid":1782,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401602","trainingLevel":"Intern \n}}","citation":"Angus DC, <i>et al</i>. \"A randomized trial of protocol-based care for early septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(10):1683-1693.","subspecialties":"Critical Care","expansion":"Protocolized Care for Early Septic Shock","briefResultsDescription":"No difference for EGDT vs. standard protocol vs. usual care for septic shock","published":"2014-05-01","pageName":"ProCESS","diseases":"Sepsis","abbreviation":"ProCESS","title":"A randomized trial of protocol-based care for early septic shock","pmid":"24635773"},{"timestamp":"2013-03-25T00:56:44Z","briefDesignDescription":"ASA-dipyridamole vs. clopidogrel in stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805002","pageid":1082,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805002","trainingLevel":"Resident","citation":"Sacco RL, <i>et al</i>. \"Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke\". <i>The New England Journal of Medicine</i>. 2008. 359(12):1238-1251.","subspecialties":"Neurology","expansion":"Prevention Regimen for Effectively Avoiding Second Strokes","briefResultsDescription":"Similar efficacy but less bleeding with clopidogrel","published":"2008-09-18","pageName":"PRoFESS","diseases":"Stroke","abbreviation":"PROFESS","title":"Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke","pmid":"18753638"},{"timestamp":"2012-05-21T16:01:07Z","briefDesignDescription":"Procalcitonin-guided antibiotics","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61879-1/fulltext","pageid":434,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673609618791.pdf","trainingLevel":"resident","citation":"Bouadma L, <i>et al</i>. \"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units\". <i>The Lancet</i>. 2010. 375(9713):463-74.","subspecialties":"Critical Care;Infectious Disease","expansion":"Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients","briefResultsDescription":"Procalcitonin noninferior and led to fewer days on antibiotics","published":"2010-02-06","pageName":"PRORATA","diseases":"Critical Illness","abbreviation":"PRORATA","title":"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units","pmid":"20097417"},{"timestamp":"2013-06-21T20:27:16Z","briefDesignDescription":"Prone ventilation in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1214103","pageid":1479,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214103","trainingLevel":"fellow\n}}","citation":"Guérin C, <i>et al</i>. \"Prone positioning in severe acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2013. 368(23):2159-2168.","subspecialties":"Critical Care","expansion":"Proning Severe ARDS Patients","briefResultsDescription":"Intermittent prone positioning improves survival in severe ARDS","published":"2013-06-06","pageName":"PROSEVA","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"PROSEVA","title":"Prone positioning in severe acute respiratory distress syndrome","pmid":"23688302"},{"timestamp":"2014-09-24T22:13:18Z","briefDesignDescription":"Pravastatin vs. atorvastatin after ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa040583","pageid":1338,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040583","trainingLevel":"Intern\n}}","citation":"Cannon CP, <i>et al</i>. \"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2004. 350(15):1495-1504.","subspecialties":"Cardiology","expansion":"Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22","briefResultsDescription":"High-dose atorvastatin is superior to moderate-dose pravastatin at reducing CV events after ACS","published":"2004-04-08","pageName":"PROVE IT-TIMI 22","diseases":"Acute Coronary Syndrome;Hyperlipidemia","abbreviation":"PROVE IT-TIMI 22","title":"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes","pmid":"15007110"},{"timestamp":"2014-09-17T23:33:52Z","briefDesignDescription":"Activated protein C in severe sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200103083441001","pageid":983,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200103083441001","trainingLevel":"Resident","citation":"Bernard GR, <i>et al</i>. \"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis\". <i>The New England Journal of Medicine</i>. 2001. 344(10):699-709.","subspecialties":"Critical Care","expansion":"Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis","briefResultsDescription":"Improved survival with APC but not seen in subsequent larger PROWESS-SHOCK trial","published":"2001-03-08","pageName":"PROWESS","diseases":"Sepsis;Shock","abbreviation":"PROWESS","title":"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis","pmid":"11236773"},{"timestamp":"2014-09-17T23:34:32Z","briefDesignDescription":"Activated protein C in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1202290","pageid":977,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1202290","trainingLevel":"Resident","citation":"Ranieri VM, <i>et al</i>. \"Drotrecogin Alfa (Activated) in Adults with Septic Shock\". <i>The New England Journal of Medicine</i>. 2012. 366(22):2055-2064.","subspecialties":"Critical Care","expansion":"Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock","briefResultsDescription":"No survival benefit at 28 or 90 days, in contrast to PROWESS","published":"2012-05-31","pageName":"PROWESS-SHOCK","diseases":"Sepsis;Shock","abbreviation":"PROWESS-SHOCK","title":"Drotrecogin Alfa (Activated) in Adults with Septic Shock","pmid":"22616830"},{"timestamp":"2014-05-22T00:30:05Z","briefDesignDescription":"Lenient vs. strict rate control in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1001337","pageid":181,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001337","trainingLevel":"Resident\n}}","citation":"Van Gelder IC, <i>et al</i>. \"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2010. 362(15):1363-73.","subspecialties":"Cardiology","expansion":"Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II","briefResultsDescription":"Lenient rate control is as effective as strict rate control","published":"2010-04-15","pageName":"RACE II","diseases":"Atrial Fibrillation","abbreviation":"RACE II","title":"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation","pmid":"20231232"},{"timestamp":"2014-06-13T06:10:06Z","briefDesignDescription":"Spironolactone in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199909023411001","pageid":11,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199909023411001","trainingLevel":"Intern\n}}","citation":"Pitt B, <i>et al</i>. \"The effect of spironolactone on morbidity and mortality in patients with severe heart failure\". <i>New England Journal of Medicine</i>. 1999. 341(10):709-717.","subspecialties":"Cardiology","expansion":"Randomized Aldactone Evaluation Study","briefResultsDescription":"Spironolactone reduces all-cause mortality by 30% in severe HFrEF","published":"1999-09-02","pageName":"RALES","diseases":"Heart Failure","abbreviation":"RALES","title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","pmid":"10471456"},{"timestamp":"2013-03-05T21:39:54Z","briefDesignDescription":"Rituximab vs. cyclophosphamide in ANCA-associated vasculitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0909905","pageid":1214,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909905","trainingLevel":"Fellow","citation":"Stone JH, <i>et al</i>. \"Rituximab versus cyclophosphamide for ANCA-associated vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):221-232.","subspecialties":"Rheumatology","expansion":"Rituximab in ANCA-Associated Vasculitis","briefResultsDescription":"Rituximab noninferior to cyclophosphamide in ANCA-associated vasculitis","published":"2010-07-15","pageName":"RAVE","diseases":"Vasculitis","abbreviation":"RAVE","title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","pmid":"20647199"},{"timestamp":"2014-10-23T16:27:56Z","briefDesignDescription":"Dabigatran in mechanical heart valves","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300615","pageid":1707,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300615","trainingLevel":"Resident\n}}","citation":"Eikelboom JW, <i>et al</i>. \"Dabigatran versus warfarin in patients with mechanical heart valves\". <i>The New England Journal of Medicine</i>. 2013. 369(13):1206-1214.","subspecialties":"Cardiology;Hematology","expansion":"Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement","briefResultsDescription":"Dabigatran has more thromboembolism and bleeding than warfarin","published":"2013-09-26","pageName":"RE-ALIGN","diseases":"Valvular Disease","abbreviation":"RE-ALIGN","title":"Dabigatran versus warfarin in patients with mechanical heart valves","pmid":"23991661"},{"timestamp":"2014-10-23T16:25:56Z","briefDesignDescription":"Dabigatran vs. warfarin in VTE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0906598","pageid":973,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906598","trainingLevel":"fellow\n}}","citation":"Schulman S, <i>et al</i>. \"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism\". <i>New England Journal of Medicine</i>. 2009. 361(24):2342-52.","subspecialties":"Hematology;Pulmonology","expansion":"Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism","briefResultsDescription":"Dabigatran non-inferior to warfarin for VTE recurrence, but dabigatran yielded less bleeding","published":"2009-12-10","pageName":"RE-COVER","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","abbreviation":"RE-COVER","title":"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism","pmid":"19966341"},{"timestamp":"2014-10-23T16:01:38Z","briefDesignDescription":"Dabigatran vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0905561","pageid":178,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905561","trainingLevel":"Resident\n}}","citation":"Connolly SJ, <i>et al</i>. \"Dabigatran versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2009. 361(12):1139-51.","subspecialties":"Cardiology","expansion":"Randomized Evaluation of Long-Term Anticoagulation Therapy","briefResultsDescription":"High-dose dabigatran reduces stroke risk without increasing major bleeding in atrial fibrillation","published":"2009-09-17","pageName":"RE-LY","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"RE-LY","title":"Dabigatran versus warfarin in patients with atrial fibrillation","pmid":"19717844"},{"timestamp":"2014-09-07T15:08:46Z","briefDesignDescription":"Darbepoetin in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1214865","pageid":1842,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214865","trainingLevel":"Fellow\n}}","citation":"Swedberg K, <i>et al</i>. \"Treatment of anemia with darbepoetin alfa in systolic heart failure\". <i>The New England Journal of Medicine</i>. 2013. 368(13):1210-9.","subspecialties":"Cardiology;Hematology","expansion":"Reduction of Events by Darbepoetin Alfa in Heart Failure","briefResultsDescription":"Darbepoetin does not improve clinical outcomes in HF with anemia","published":"2013-03-28","pageName":"RED-HF","diseases":"Heart Failure;Anemia","abbreviation":"RED-HF","title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","pmid":"23473338"},{"timestamp":"2013-10-09T13:16:45Z","briefDesignDescription":"5d vs. 14d steroids in acute COPD","fulltexturl":null,"pageid":1615,"pdfurl":null,"trainingLevel":"Intern","citation":"Leuppi JD, <i>et al</i>. \"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial\". <i>JAMA</i>. 2013. 309(21):2223-2231.","subspecialties":"Pulmonology","expansion":"Reduction in the Use of Corticosteroids in Exacerbated COPD","briefResultsDescription":"5d steroids noninferior to 14d in acute COPD","published":"2013-06-05","pageName":"REDUCE","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"REDUCE","title":"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial","pmid":"23695200"},{"timestamp":"2013-08-05T15:03:59Z","briefDesignDescription":"ARBs in diabetic nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011161","pageid":1030,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011161","trainingLevel":"Intern","citation":"Brenner BM, <i>et al</i>. \"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy\". <i>The New England Journal of Medicine</i>. 2001. 345(12):861-869.","subspecialties":"Endocrinology;Nephrology","expansion":"Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan","briefResultsDescription":"ARBs reduce progression to","published":"2001-09-20","pageName":"RENAAL","diseases":"Diabetes Mellitus;Chronic Kidney Disease","abbreviation":"RENAAL","title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","pmid":"11565518"},{"timestamp":"2013-08-15T18:48:57Z","briefDesignDescription":"PFO closure in cryptogenic stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1301440","pageid":1334,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301440","trainingLevel":"Intern","citation":"Carroll JD, <i>et al</i>. \"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke\". <i>The New England Journal of Medicine</i>. 2013. 368(12):1092-1100.","subspecialties":"Neurology;Cardiology","expansion":"Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment","briefResultsDescription":"PFO closure does not reduce recurrent CVA after cryptogenic CVA","published":"2013-03-21","pageName":"RESPECT","diseases":"Stroke;Patent Foramen Ovale;Transient Ischemic Attack","abbreviation":"RESPECT","title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","pmid":"23514286"},{"timestamp":"2014-07-11T14:28:09Z","briefDesignDescription":"Rifaximin/lactulose vs. lactulose for acute HE","fulltexturl":"http://www.nature.com/ajg/journal/v108/n9/full/ajg2013219a.html","pageid":1784,"pdfurl":"http://www.nature.com/ajg/journal/v108/n9/pdf/ajg2013219a.pdf","trainingLevel":"Intern\n}}","citation":"Sharma BC, <i>et al</i>. \"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy\". <i>The American Journal of Gastroenterology</i>. 2013. 108(9):1458-1463.","subspecialties":"Gastroenterology","expansion":"","briefResultsDescription":"Rifaximin/lactulose improved rates of HE reversal and survival, reduced hospital LOS","published":"2013-09-01","pageName":"Rifaximin and Lactulose for HE","diseases":"Hepatic Encephalopathy","abbreviation":"","title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","pmid":"23877348"},{"timestamp":"2014-10-01T17:51:44Z","briefDesignDescription":"Early goal-directed therapy in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010307","pageid":60,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010307","trainingLevel":"Student","citation":"Rivers E, <i>et al</i>. \"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock\". <i>The New England Journal of Medicine</i>. 2001. 345(19):1368-1377.","subspecialties":"Critical Care;Emergency Medicine","expansion":"","briefResultsDescription":"Early goal-directed therapy decreased mortality and morbiditiy in sepsis","published":"2001-11-08","pageName":"Rivers Trial","diseases":"Sepsis;Shock","abbreviation":"","title":"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock","pmid":"11794169"},{"timestamp":"2014-10-23T16:02:02Z","briefDesignDescription":"Rivaroxaban vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009638","pageid":1358,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009638","trainingLevel":"Student\n}}","citation":"Patel MR, <i>et al</i>. \"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 365(10):883-891.","subspecialties":"Cardiology;Neurology","expansion":"Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation","briefResultsDescription":"Rivaroxaban is noninferior to warfarin for stroke/embolization prevention in nonvalvular AF","published":"2011-09-08","pageName":"ROCKET AF","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ROCKET AF","title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","pmid":"21830957"},{"timestamp":"2014-09-24T22:15:54Z","briefDesignDescription":"Sertraline for depression post-ACS","fulltexturl":"http://jama.ama-assn.org/content/288/6/701.full","pageid":423,"pdfurl":"http://jama.ama-assn.org/content/288/6/701.full.pdf","trainingLevel":"Resident","citation":"Glassman AH, <i>et al</i>. \"Sertraline treatment of major depression in patients with acute MI or unstable angina\". <i>Journal of the American Medical Association</i>. 2002. 288(6):701-709.","subspecialties":"Psychiatry;Cardiology","expansion":"Sertraline Antidepressant Heart Attack Randomized Trial","briefResultsDescription":"Sertraline improves symptoms without adverse CV effects","published":"2002-08-14","pageName":"SADHART","diseases":"Depression;Acute Coronary Syndrome","abbreviation":"SADHAT","title":"Sertraline treatment of major depression in patients with acute MI or unstable angina","pmid":"12169073"},{"timestamp":"2014-10-20T05:00:23Z","briefDesignDescription":"Albumin vs. saline in ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa040232","pageid":285,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040232","trainingLevel":"Intern\n}}","citation":"Finfer S, <i>et al</i>. \"A comparison of albumin and saline for fluid resuscitation in the intensive care unit\". <i>The New England Journal of Medicine</i>. 2004. 350(22):2247-2256.","subspecialties":"Critical Care","expansion":"Saline versus Albumin Fluid Evaluation","briefResultsDescription":"No mortality difference (except worse mortality with albumin for TBI)","published":"2004-05-27","pageName":"SAFE","diseases":"Critical Illness","abbreviation":"SAFE","title":"A comparison of albumin and saline for fluid resuscitation in the intensive care unit","pmid":"15163774"},{"timestamp":"2014-09-24T22:25:59Z","briefDesignDescription":"Captopril in MI with LV dysfunction","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199209033271001","pageid":150,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199209033271001","trainingLevel":"Resident\n}}","citation":"Pfeffer MA, <i>et al</i>. \"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial\". <i>The New England Journal of Medicine</i>. 1992. 327(10):669-677.","subspecialties":"Cardiology","expansion":"Survival and Ventricular Enlargement Trial","briefResultsDescription":"Captopril improves survival","published":"1992-09-03","pageName":"SAVE","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Heart Failure","abbreviation":"SAVE","title":"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial","pmid":"1386652"},{"timestamp":"2014-06-13T06:22:51Z","briefDesignDescription":"Amiodarone or ICD in severe HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa043399","pageid":40,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa043399","trainingLevel":"Intern\n}}","citation":"Bardy GH, <i>et al</i>. \"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure\". <i>The New England Journal of Medicine</i>. 2005. 252(3):225-37.","subspecialties":"Cardiology","expansion":"Sudden Cardiac Death in Heart Failure Trial","briefResultsDescription":"ICD reduces mortality by 23% in class II-III HFrEF","published":"2005-01-20","pageName":"SCD-HeFT","diseases":"Heart Failure","abbreviation":"SCD-HeFT","title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","pmid":"15659722"},{"timestamp":"2014-05-27T04:59:32Z","briefDesignDescription":"Dexmedetomidine vs. midazolam for sedation","fulltexturl":"http://jama.ama-assn.org/content/301/5/489.long","pageid":353,"pdfurl":"http://jama.ama-assn.org/content/301/5/489.full.pdf","trainingLevel":"Resident","citation":"Riker RR, <i>et al</i>. \"Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients\". <i>Journal of American Medical Association</i>. 2009. 301(5):489-499.","subspecialties":"Critical Care","expansion":"Safety and Efficacy of Dexmedetomidine Compared with Midazolam","briefResultsDescription":"↓ delirium, ↓ ventilator days with dexmedetomidine","published":"2009-02-04","pageName":"SEDCOM","diseases":"Critical Illness","abbreviation":"SEDCOM","title":"Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients","pmid":"19188334"},{"timestamp":"2014-05-27T21:07:18Z","briefDesignDescription":"MAP 65-70 vs. 80-85 mmHg in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1312173","pageid":1779,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1312173","trainingLevel":"Resident\n}}","citation":"Asfar P, <i>et al</i>. \"High versus low blood-pressure target in patients with septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(17):1583-1593.","subspecialties":"Critical Care","expansion":"Sepsis and Mean Arterial Pressure","briefResultsDescription":"No difference for higher MAP in sepsis except renal protection in vascular disease","published":"2014-04-23","pageName":"SEPSISPAM","diseases":"Sepsis;Shock","abbreviation":"SEPSISPAM","title":"High versus low blood-pressure target in patients with septic shock","pmid":"24635770"},{"timestamp":"2014-09-24T21:56:53Z","briefDesignDescription":"Early PCI/CABG in MI + shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199908263410901","pageid":388,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199908263410901","trainingLevel":"Resident\n}}","citation":"Hochman JS, <i>et al</i>. \"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 1999. 341(9):625-634.","subspecialties":"Cardiology;Critical Care","expansion":"SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK","briefResultsDescription":"Early PCI/CABG improves survival in acute MI and cardiogenic shock","published":"1999-08-26","pageName":"SHOCK","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Shock","abbreviation":"SHOCK","title":"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock","pmid":"10460813"},{"timestamp":"2012-08-28T16:50:41Z","briefDesignDescription":"Salmeterol in asthma","fulltexturl":"http://chestjournal.chestpubs.org/content/129/1/15.long","pageid":512,"pdfurl":"http://chestjournal.chestpubs.org/content/129/1/15.full.pdf","trainingLevel":"intern","citation":"Nelson HS, <i>et al</i>. \"The salmeterol multicenter asthma research trial\". <i>Chest</i>. 2006. 129(1):15-26.","subspecialties":"Pulmonology","expansion":"Salmeterol Multicenter Asthma Research Trial","briefResultsDescription":"Salmeterol increases death in subgroups","published":"2006-01-01","pageName":"SMART","diseases":"Asthma","abbreviation":"SMART","title":"The salmeterol multicenter asthma research trial","pmid":"16424409"},{"timestamp":"2014-08-17T15:42:13Z","briefDesignDescription":"Dopamine vs. norepinephrine in shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0907118","pageid":113,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907118","trainingLevel":"Intern","citation":"De Backer D, <i>et al</i>. \"Comparison of dopamine and norepinephrine in the treatment of shock\". <i>The New England Journal of Medicine</i>. 2010. 362(9):779-89.","subspecialties":"Critical Care;Emergency Medicine","expansion":"Sepsis Occurrence in Acutely Ill Patients II","briefResultsDescription":"Norepinephrine reduces mortality","published":"2010-03-04","pageName":"SOAP II","diseases":"Sepsis;Shock","abbreviation":"SOAP II","title":"Comparison of dopamine and norepinephrine in the treatment of shock","pmid":"20200382"},{"timestamp":"2014-06-13T07:07:04Z","briefDesignDescription":"Enalapril in moderate-severe HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199108013250501","pageid":394,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501","trainingLevel":"Resident\n}}","citation":"Yusuf S, <i>et al</i>. \"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure\". <i>The New England Journal of Medicine</i>. 1991. 325(5):293-302.","subspecialties":"Cardiology","expansion":"Studies of Left Ventricular Dysfunction","briefResultsDescription":"Enalapril reduces mortality and HF hospitalizations in HFrEF","published":"1991-08-01","pageName":"SOLVD","diseases":"Heart Failure","abbreviation":"SOLVD","title":"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure","pmid":"2057034"},{"timestamp":"2014-07-27T15:59:47Z","briefDesignDescription":"Infliximab ± azathioprine induction in Crohn's disease","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0904492","pageid":1863,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904492","trainingLevel":"Intern","citation":"Colombel JF, <i>et al</i>. \"Infliximab, azathioprine, or combination therapy for Crohn's disease\". <i>The New England Journal of Medicine</i>. 2010. 362(15):1383-1395.","subspecialties":"Gastroenterology","expansion":"Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease","briefResultsDescription":"Combination therapy better than infliximab or azathioprine for Crohn's disease induction therapy","published":"2010-04-15","pageName":"SONIC","diseases":"Inflammatory Bowel Disease;Crohn's Disease","abbreviation":"SONIC","title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","pmid":"20393175"},{"timestamp":"2014-10-17T07:40:24Z","briefDesignDescription":"Atorvastatin after stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa061894","pageid":461,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa061894","trainingLevel":"intern","citation":"Amarenco P, <i>et al</i>. \"High-dose atorvastatin after stroke or transient ischemic attack\". <i>The New England Journal of Medicine</i>. 2006. 355(6):549-559.","subspecialties":"Neurology","expansion":"Stroke Prevention by Aggressive Reduction in Cholesterol Levels","briefResultsDescription":"Atorvastatin ↓stroke risk in general but slightly ↑hemorrhagic strokes","published":"2006-08-10","pageName":"SPARCL","diseases":"Stroke;Hyperlipidemia;Transient Ischemic Attack","abbreviation":"SPARCL","title":"High-dose atorvastatin after stroke or transient ischemic attack","pmid":"16899775"},{"timestamp":"2013-06-20T19:29:27Z","briefDesignDescription":"Tamoxifen vs. raloxifene in breast cancer prevention","fulltexturl":"http://jama.jamanetwork.com/article.aspx?articleid","pageid":963,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/5028/JOC60074.pdf","trainingLevel":"Fellow","citation":"Vogel VG, <i>et al</i>. \"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes\". <i>Journal of the American Medical Association</i>. 2006. 295(23):2727-2741.","subspecialties":"Oncology","expansion":"Study of Tamoxifen and Raloxifene (NSABP P-2)","briefResultsDescription":"Similar reduction in breast cancer risk but fewer adverse effects with raloxifene","published":"2006-06-21","pageName":"STAR","diseases":"Breast Cancer","abbreviation":"STAR","title":"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes","pmid":"16754727"},{"timestamp":"2013-09-04T17:04:52Z","briefDesignDescription":"Tiered approach for depression","fulltexturl":"","pageid":1564,"pdfurl":"http://ajp.psychiatryonline.org/data/Journals/AJP/3782/06aj1905.PDF","trainingLevel":"Resident","citation":"Rush AJ <i>et al</i>. \"Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report\". <i>The American Journal of Psychiatry</i>. 2006. 163(11):1905-1917.","subspecialties":"Psychiatry","expansion":"Sequenced Treatment Alternatives to Relieve Depression","briefResultsDescription":"Most patients achieved remission in first two steps","published":"2006-11-01","pageName":"STAR-D","diseases":"Depression","abbreviation":"STAR-D","title":"Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report","pmid":"17074942"},{"timestamp":"2014-06-13T06:39:16Z","briefDesignDescription":"CABG in ischemic HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1100356","pageid":471,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100356","trainingLevel":"Resident\n}}","citation":"Velazquez EJ, <i>et al</i>. \"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction\". <i>The New England Journal of Medicine</i>. 2011. 354(17):1607-1616.","subspecialties":"Cardiology","expansion":"Surgical Treatment for Ischemic Heart Failure","briefResultsDescription":"No mortality benefit with CABG vs. OMT though improved CV outcomes","published":"2011-04-28","pageName":"STICH","diseases":"Heart Failure;Coronary Artery Disease","abbreviation":"STICH","title":"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction","pmid":"21463150"},{"timestamp":"2014-10-21T17:56:41Z","briefDesignDescription":"B-R vs. R-CHOP for indolent lymphomas","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61763-2","pageid":1664,"pdfurl":"http://bit.ly/1owpykX","trainingLevel":"fellow\n}}","citation":"Rummel MJ, <i>et al</i>. \"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial\". <i>The Lancet</i>. 2013. 381(9873):1203-10.","subspecialties":"Oncology;Hematology","expansion":"Study Group Indolent Lymphomas","briefResultsDescription":"B-R superior to R-CHOP in PFS, similar in OS, less toxic","published":"2013-04-03","pageName":"StiL","diseases":"Lymphoma","abbreviation":"StiL","title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","pmid":"23433739"},{"timestamp":"2014-06-26T14:53:03Z","briefDesignDescription":"Cytoreductive nephrectomy in metastatic RCC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa003013","pageid":1845,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa003013","trainingLevel":"Fellow","citation":"Flanigan RC, <i>et al</i>. \"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer\". <i>The New England Journal of Medicine</i>. 2001. 345(23):1655-9.","subspecialties":"Oncology;Surgery;Urology","expansion":"","briefResultsDescription":"Cytoreductive nephrectomy improves survival in mRCC","published":"2001-12-06","pageName":"SWOG 8949","diseases":"Renal Cell Carcinoma","abbreviation":"SWOG 8949","title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","pmid":"11759643"},{"timestamp":"2013-11-26T02:02:32Z","briefDesignDescription":"PCI vs. CABG in severe CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0804626","pageid":525,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804626","trainingLevel":"Resident","citation":"Serruys PW, <i>et al</i>. \"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2009. 360(10):961-972.","subspecialties":"Cardiology;Surgery","expansion":"Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery","briefResultsDescription":"CABG reduces major CV events with 3VD or LM disease","published":"2009-03-05","pageName":"SYNTAX","diseases":"Coronary Artery Disease","abbreviation":"SYNTAX","title":"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease","pmid":"19228612"},{"timestamp":"2014-05-11T18:31:15Z","briefDesignDescription":"Atorvastatin in stable CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa050461","pageid":1762,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa050461","trainingLevel":"Student","citation":"LaRosa JC, <i>et al</i>. \"Intensive lipid lowering with atorvastatin in patients with stable coronary disease\". <i>The New England Journal of Medicine</i>. 2005. 352(14):1425-1435.","subspecialties":"Cardiology","expansion":"Treating to New Targets","briefResultsDescription":"Atorvastatin 80 mg better than 10 mg for major CV events in stable CAD","published":"2005-04-07","pageName":"TNT","diseases":"Coronary Artery Disease;Hyperlipidemia","abbreviation":"TNT","title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","pmid":"15755765"},{"timestamp":"2014-07-15T15:30:25Z","briefDesignDescription":"Spironolactone for HFpEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1313731","pageid":1797,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313731","trainingLevel":"Resident\n}}","citation":"Pitt B, <i>et al</i>. \"Spironolactone for heart failure with preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1383-1392.","subspecialties":"Cardiology","expansion":"Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist","briefResultsDescription":"Spironolactone doesn't reduce CV mortality, aborted cardiac arrest or HF hospitalizations in HFpEF","published":"2014-04-20","pageName":"TOPCAT","diseases":"Heart Failure","abbreviation":"TOPCAT","title":"Spironolactone for heart failure with preserved ejection fraction","pmid":"24716680"},{"timestamp":"2012-09-16T11:23:34Z","briefDesignDescription":"Salmeterol/fluticasone in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa063070","pageid":124,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa063070","trainingLevel":"Student","citation":"Calverley PM, <i>et al</i>. \"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease\". <i>The New England Journal of Medicine</i>. 2007. 356(8):775-789.","subspecialties":"Pulmonology","expansion":"Towards a Revolution in COPD Health","briefResultsDescription":"Trend towards mortality benefit","published":"2007-02-22","pageName":"TORCH","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"TORCH","title":"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease","pmid":"17314337"},{"timestamp":"2014-08-28T01:01:02Z","briefDesignDescription":"Darbepoetin in CKD and T2DM","fulltexturl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907845","pageid":5,"pdfurl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0907845","trainingLevel":"Resident","citation":"Pfeffer MA, <i>et al</i>. \"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease\". <i>The New England Journal of Medicine</i>. 2009. 361(21):2019-32.","subspecialties":"Nephrology;Hematology;Endocrinology","expansion":"Trial to Reduce Cardiovascular Events With Aranesp Therapy","briefResultsDescription":"No mortality benefit when targeting higher hemoglobin with ESAs in patients with CKD and T2DM","published":"2009-11-19","pageName":"TREAT","diseases":"Chronic Kidney Disease;Anemia;Diabetes Mellitus","abbreviation":"TREAT","title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","pmid":"19880844"},{"timestamp":"2014-10-01T17:47:50Z","briefDesignDescription":"ICU transfusion thresholds","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199902113400601","pageid":104,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199902113400601","trainingLevel":"Intern","citation":"Hebert PC, <i>et al</i>. \"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care\". <i>The New England Journal of Medicine</i>. 1999. 340(6):409-417.","subspecialties":"Critical Care;Hematology","expansion":"Transfusion Requirements in Critical Care","briefResultsDescription":"Restrictive hemoglobin goals improved mortality","published":"1999-02-11","pageName":"TRICC","diseases":"Anemia","abbreviation":"TRICC","title":"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care","pmid":"9971864"},{"timestamp":"2014-09-26T18:00:07Z","briefDesignDescription":"Prasugrel vs. clopidogrel in ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0706482","pageid":1398,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706482","trainingLevel":"Resident\n}}","citation":"Wiviott ST, <i>et al</i>. \"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2007. 357(20):2001-2015.","subspecialties":"Cardiology","expansion":"Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38","briefResultsDescription":"Prasugrel decreases CV mortality/morbidity, increases bleeding","published":"2007-11-15","pageName":"TRITON-TIMI 38","diseases":"Acute Coronary Syndrome","abbreviation":"TRITON-TIMI 38","title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","pmid":"17982182"},{"timestamp":"2014-07-15T12:01:37Z","briefDesignDescription":"33 vs. 36°C body temperature after cardiac arrest","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1310519","pageid":1783,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310519","trainingLevel":"Resident \n}}","citation":"Nielsen N, <i>et al</i>. \"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2013. 369(23):2197-2206.","subspecialties":"Cardiology;Neurology;Critical Care","expansion":"arget Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest","briefResultsDescription":"33°C cooling provides no survival benefit over 36°C","published":"2014-03-19","pageName":"TTM","diseases":"Cardiac Arrest","abbreviation":"TTM","title":"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest","pmid":"24237006"},{"timestamp":"2014-10-01T13:34:14Z","briefDesignDescription":"Twice-daily RT in limited SCLC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199901283400403","pageid":1773,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199901283400403","trainingLevel":"Resident","citation":"Turrisi AT, <i>et al</i>. \"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide\". <i>The New England Journal of Medicine</i>. 1999. 340(4):265-271.","subspecialties":"Oncology;Pulmonology;Radiation Oncology","expansion":"","briefResultsDescription":"Twice-daily RT with better response, PFS, survival than once-daily RT for limited SCLC","published":"1999-01-28","pageName":"Twice-daily RT for SCLC","diseases":"Lung Cancer","abbreviation":"","title":"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide","pmid":"9920950"},{"timestamp":"2013-11-02T15:38:25Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140673698070196","pageid":253,"pdfurl":"","trainingLevel":"Intern","citation":"Turner R, <i>et al</i>. \"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes\". <i>The Lancet</i>. 1998. 352(9131):837-53.","subspecialties":"Endocrinology","expansion":"United Kingdom Prospective Diabetes Study","briefResultsDescription":"Reduction in microvascular complications","published":"1998-09-12","pageName":"UKPDS 33","diseases":"Diabetes Mellitus","abbreviation":"UKPDS","title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes","pmid":"9742976"},{"timestamp":"2014-05-11T21:55:20Z","briefDesignDescription":"Metformin in T2DM","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2898%2907037-8/fulltext","pageid":1747,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673698070378.pdf","trainingLevel":"Intern","citation":"UKPDS Study Group. \"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.\". <i>The Lancet</i>. 1998. 352(9131):854-865.","subspecialties":"Endocrinology","expansion":"UK Prospective Diabetes Study 34","briefResultsDescription":"Metformin better than diet alone in T2DM","published":"1998-11-07","pageName":"UKPDS 34","diseases":"Diabetes Mellitus","abbreviation":"UKPDS 34","title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.","pmid":"9742977"},{"timestamp":"2012-10-29T23:28:48Z","briefDesignDescription":"Tiotropium in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805800","pageid":123,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805800","trainingLevel":"Resident","citation":"Tashkin DP, <i>et al</i>. \"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease\". <i>The New England Journal of Medicine</i>. 2008. 395(15):1543-1554.","subspecialties":"Pulmonology","expansion":"Understanding Potential Long-Term Impacts on Function with Tiotropium","briefResultsDescription":"Decreased exacerbations and mortality","published":"2008-10-09","pageName":"UPLIFT","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"UPLIFT","title":"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease","pmid":"18836213"},{"timestamp":"2014-06-22T17:29:05Z","briefDesignDescription":"ISDN/hydralazine in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198606123142404","pageid":155,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198606123142404","trainingLevel":"student\n}}","citation":"Cohn JN, <i>et al</i>. \"Effect of vasodilator therapy on mortality in chronic congestive heart failure\". <i>The New England Journal of Medicine</i>. 1986. 314(24):1547-52.","subspecialties":"Cardiology","expansion":"Vasodilator Heart Failure Trial","briefResultsDescription":"Trend towards mortality benefit in ISDN/hydralazine","published":"1986-06-12","pageName":"V-HeFT","diseases":"Heart Failure","abbreviation":"V-HeFT","title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","pmid":"3520315"},{"timestamp":"2014-09-24T22:23:54Z","briefDesignDescription":"Aspirin in unstable angina","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198308183090703","pageid":261,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198308183090703","trainingLevel":"Resident\n}}","citation":"Lewis HD, <i>et al</i>. \"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study\". <i>The New England Journal of Medicine</i>. 1983. 309(7):396-403.","subspecialties":"Cardiology","expansion":null,"briefResultsDescription":"Aspirin decreases mortality","published":"1983-08-18","pageName":"VA Cooperative Study","diseases":"Acute Coronary Syndrome","abbreviation":null,"title":"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study","pmid":"6135989"},{"timestamp":"2014-05-27T14:55:58Z","briefDesignDescription":"ACE+ARB in DM nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1303154","pageid":1798,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1303154","trainingLevel":"Resident\n}}","citation":"Fried LF, <i>et al</i>. \"Combined angiotensin inhibition for the treatment of diabetic nephropathy\". <i>The New England Journal of Medicine</i>. 2013. 369(20):1892-1903.","subspecialties":"Nephrology;Endocrinology","expansion":"Veterans Affairs Nephropathy in Diabetes","briefResultsDescription":"ACE+ARB no more effective than monotherapy, increases complications","published":"2013-11-14","pageName":"VA-NEPHRON D","diseases":"Diabetes Mellitus;Diabetic Nephropathy","abbreviation":"VA NEPHRON-D","title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","pmid":"24206457"},{"timestamp":"2014-09-25T14:42:04Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0808431","pageid":254,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0808431","trainingLevel":"Resident","citation":"Duckworth W, <i>et al</i>. \"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2009. 360(2):129-39.","subspecialties":"Endocrinology","expansion":"Veterans Affairs Diabetes Trial","briefResultsDescription":"No effect on macrovascular or severe microvascular outcomes","published":"2009-01-08","pageName":"VADT","diseases":"Diabetes Mellitus","abbreviation":"VADT","title":"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes","pmid":"19092145"},{"timestamp":"2014-08-24T17:55:57Z","briefDesignDescription":"Valsartan in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010713","pageid":20,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010713","trainingLevel":"Resident\n}}","citation":"Cohn JN, <i>et al</i>. \"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure\". <i>New England Journal of Medicine</i>. 2001. 345(23):1667-75.","subspecialties":"Cardiology","expansion":"Valsartan Heart Failure Trial","briefResultsDescription":"No mortality benefit of valsartan in NYHA II-IV HF","published":"2001-12-06","pageName":"Val-HeFT","diseases":"Heart Failure","abbreviation":"Val-HeFT","title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","pmid":"11759645"},{"timestamp":"2014-09-24T22:25:53Z","briefDesignDescription":"Valsartan vs. captopril in MI with LV dysfunction","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa032292","pageid":462,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa032292","trainingLevel":"Resident\n}}","citation":"Pfeffer, MA <i>et al</i>. \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both\". <i>The New England Journal of Medicine</i>. 2003. 349(20):1893-1903.","subspecialties":"Cardiology","expansion":"Valsartan in Acute Myocardial Infarction Trial","briefResultsDescription":"Valsartan as effective as captopril","published":"2003-11-13","pageName":"VALIANT","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"VALIANT","title":"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both","pmid":"12921816"},{"timestamp":"2014-07-28T20:00:24Z","briefDesignDescription":"Vancomycin vs. metronidazole in C. difficile","fulltexturl":"http://cid.oxfordjournals.org/content/45/3/302.long","pageid":6,"pdfurl":"http://cid.oxfordjournals.org/content/45/3/302.full.pdf","trainingLevel":"Intern","citation":"Zar FA, <i>et al</i>. \"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity\". <i>Clinical Infectious Diseases</i>. 2007. 45(3):302-7.","subspecialties":"Infectious Disease;Gastroenterology","expansion":null,"briefResultsDescription":"Vancomycin is superior to metronidazole in severe C. difficile-associated diarrhea","published":"2007-08-01","pageName":"Vancomycin vs. Metronidazole in C. difficile Diarrhea","diseases":"Clostridium difficile","abbreviation":null,"title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","pmid":"17599306"},{"timestamp":"2014-08-22T06:10:48Z","briefDesignDescription":"Vasopressin in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa067373","pageid":1910,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa067373","trainingLevel":"Resident","citation":"Russel JA, <i>et al</i>. \"Vasopressin versus norepinephrine infusion in patients with septic shock\". <i>The New England Journal of Medicine</i>. 2008. 358(9):877-887.","subspecialties":"Critical Care","expansion":"Vasopressin and Septic Shock Trial","briefResultsDescription":"Vasopressin doesn't reduce mortality in shock","published":"2008-02-28","pageName":"VASST","diseases":"Sepsis;Shock","abbreviation":"VASST","title":"Vasopressin versus norepinephrine infusion in patients with septic shock","pmid":"18305265"},{"timestamp":"2014-10-27T16:49:12Z","briefDesignDescription":"Aspirin after VTE treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1114238","pageid":1244,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1114238","trainingLevel":"resident\n}}","citation":"Becattini C, <i>et al</i>. \"Aspirin for preventing the recurrence of venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2012. 366(21):1959-1967.","subspecialties":"Hematology","expansion":"Warfarin and Aspirin","briefResultsDescription":"Aspirin reduces recurrent VTE","published":"2012-05-24","pageName":"WARFASA","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","abbreviation":"WARFASA","title":"Aspirin for preventing the recurrence of venous thromboembolism","pmid":"22621626"},{"timestamp":"2014-10-06T13:42:02Z","briefDesignDescription":"Postmenopausal estrogen/progesterone","fulltexturl":null,"pageid":1507,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4840/JOC21036.pdf","trainingLevel":"Student","citation":"Rossouw JE, <i>et al</i>. \"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial\". <i>The Journal of the American Medical Association</i>. 2002. 288(3):321-333.","subspecialties":"Gynecology;Endocrinology","expansion":"Women's Health Initiative Estrogen and Progestin Trial","briefResultsDescription":"Postmenopausal estrogen/progesterone HRT increases rates of MI and breast cancer","published":"2002-07-17","pageName":"WHI","diseases":"Coronary Artery Disease;Menopause","abbreviation":"WHI E+P","title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial","pmid":"12117397"},{"timestamp":"2013-08-27T20:25:03Z","briefDesignDescription":"Pravastatin in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199511163332001","pageid":172,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199511163332001","trainingLevel":"Resident","citation":"Shepherd J, <i>et al</i>. \"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia\". <i>The New England Journal of Medicine</i>. 1995. 333(20):1301-1308.","subspecialties":"Cardiology","expansion":"West of Scotland Coronary Prevention Study","briefResultsDescription":"Pravastatin reduces MIs and CV mortality","published":"1995-11-16","pageName":"WOSCOPS","diseases":"Hyperlipidemia;Coronary Artery Disease","abbreviation":"WOSCOPS","title":"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia","pmid":"7566020"},{"timestamp":"2014-05-18T14:32:26Z","briefDesignDescription":"RSBI for predicting weaning","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199105233242101","pageid":75,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199105233242101","trainingLevel":"Resident\n}}","citation":"Yang KL, Tobin MJ. \"A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation\". <i>The New England Journal of Medicine</i>. 1991. 324(21):1445-1450.","subspecialties":"Pulmonology;Critical Care","expansion":"","briefResultsDescription":"RSBI predicts success and failure of weaning from mechanical ventilation","published":"1991-05-23","pageName":"Yang-Tobin Study","diseases":"Critical Illness","abbreviation":"","title":"A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation","pmid":"2023603"}]}}